CN101371822A - Stomach detention sustained and controlled release medicament releasing system and preparation method - Google Patents

Stomach detention sustained and controlled release medicament releasing system and preparation method Download PDF

Info

Publication number
CN101371822A
CN101371822A CNA2008101474457A CN200810147445A CN101371822A CN 101371822 A CN101371822 A CN 101371822A CN A2008101474457 A CNA2008101474457 A CN A2008101474457A CN 200810147445 A CN200810147445 A CN 200810147445A CN 101371822 A CN101371822 A CN 101371822A
Authority
CN
China
Prior art keywords
medicine
release
coating
stomach
layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2008101474457A
Other languages
Chinese (zh)
Other versions
CN101371822B (en
Inventor
姜庆伟
郑俊丽
杨文斌
刘全志
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BEIJING TIANHENG DRUG RESEARCH INSTITUTE
Original Assignee
BEIJING TIANHENG MEDICINE INST
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BEIJING TIANHENG MEDICINE INST filed Critical BEIJING TIANHENG MEDICINE INST
Priority to CN 200810147445 priority Critical patent/CN101371822B/en
Priority to KR1020117006016A priority patent/KR20110042366A/en
Priority to JP2011523290A priority patent/JP2012500230A/en
Priority to US13/059,553 priority patent/US20110171275A1/en
Priority to PCT/CN2008/072917 priority patent/WO2010020098A1/en
Priority to EP08876775A priority patent/EP2329810A4/en
Publication of CN101371822A publication Critical patent/CN101371822A/en
Application granted granted Critical
Publication of CN101371822B publication Critical patent/CN101371822B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N13/00—Investigating surface or boundary effects, e.g. wetting power; Investigating diffusion effects; Analysing materials by determining surface, boundary, or diffusion effects
    • G01N2013/006—Dissolution of tablets or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention provides a new air sac type gastric retention controlled-release medicine release system, including (1) an air sac which is formed by wrapping high molecular film-forming materials and hydrophobic materials outside a hollow sac; (2) a medicine containing layer which is composed of medicines and pharmaceutically acceptable excipient; the medicine containing layer covers the outside of the air sac and includes a medicine controlled release layer or a medicine slow release layer. If necessary, a quick release layer, which is composed of medicines and excipient and covers the outside of the controlled release layer or the slow release layer, can also be included. The air sac can also be internally filled with a certain amount of gas generant which includes carbonate and pharmaceutically acceptable organic acid. The average density of the whole formulation can be generally controlled below 0.6/cm<3> and is obviously superior to the present gastro-floating formulation on sale, and the floating time in the stomach is rather longer than a common gastro-floating formulation.

Description

Stomach detention sustained and controlled release medicament releasing system and preparation method
Technical field
The present invention relates to medical technical field, relate to a kind of new stomach detention sustained and controlled release medicament releasing system, relate in particular to stomach detention sustained control drug release system of a kind of bladder-type and preparation method thereof.
Background technology
The Entogastric lingering sustained-release preparation, it is the important form of gastric retention control drug release system, be according to hydrodynamically balanced system (The Hydronamically Balanced Sustained/controlled Drug Delivery System, HBS) principle design preparation can float on the gastric juice after oral and continues to discharge a kind of special preparation of medicine.This preparation since autologous density less than gastric content, usually be floating state under one's belt and be detained 5～6h, prolong drug makes medicine as much as possible arrive absorption site with dissolved state in the release time of gastric, improve drug absorption, improve bioavailability and prolong drug action time.Tossounian and Sheth are described in detail the floating in stomach preparation the earliest.Be referred to as " biological effectiveness preparation " (bioefficient product).Early 1980s Hofmann-La Roche company has at first released Valrelease and two floating preparation kinds of Valium CR.At present domestic also have a listing of floating in stomach preparation, as the gentamycin intragastric floating sustained-release tablet (trade name: Swibec TAB), furazolidone Entogastric lingering sheet etc.
It is generally acknowledged that ideal Entogastric lingering preparation needs following feature: 1) under the body temperature state, behind the preparation contact gastric juice, the surface energy aquation becomes the gel barrier, and the original dosage form shape of maintenance that expands; 2) composition of preparation is beneficial to preparation at Entogastric lingering, keeps floating state, and promptly the density of preparation is less than 1g/cm 33) selection of the character of medicine, consumption, adjuvant can both meet the inside and outside release characteristics that the Entogastric lingering preparation requires, and can slowly dissolve, spread, and can keep the long drug release time of gastric, generally can reach 5～6h.
The purpose of making the stomach floating preparation is:
1) promotes weak acidic drug and the absorption that the medicine of absorption window is arranged at harmonization of the stomach small intestinal epimere.
2) make that unsettled medicine is absorbed preferably at stomach in intestinal.
3) make medicine in stomach or duodenum position performance topical therapeutic effect.
4) be detained by stomach and prolong preparation, make in each section of gastrointestinal tract absorption excellent drug to absorb more fully, thereby help preparing the preparation that was administered once in a day in the time that digestive tract stops.
The buoyant factor of influence mainly contains in the tradition stomach floating preparation:
1) selecting for use of material: the hydrogel matrix density of use must be less than 1g/cm 3, and can keep the long period, also need add bleach activator and foaming agent, to reduce the density of preparation, increase floating force.
2) preparation technology: adopt full powder straight forming, to keep the space that dry powder was had more.
3) density of dry preparation and hold buoyancy.
The stomach floating preparation of bibliographical information and license adopts low-density wax material, high expanding material to increase the density that modes such as volume and aerogenesis reduce whole preparation more at present, thereby prolongs at gastric transit time.
The 4th, 101, No. 650 U.S. Patent Publication of Incorporated Foundation Microbial Chemistry Research application a kind of prescription, in this prescription, contain sodium bicarbonate, the granule of lactose and polyvidone is wrapped one deck hydroxypropyl methylcellulose.And then wrap the suspended substance that one deck contains active component pepsin inhibitor and hydroxypropyl emthylcellulose in the above, form the floating microcapsule of diameter in 0.1～2mm scope.The shortcoming of this system is a microcapsule required size in the long-time delay stomach dimensionally; Sodium bicarbonate is wrapped in the hydroxypropyl methylcellulose layer and produces gas and can not significantly reduce the density of microgranule, thereby the two big key factors that do not satisfy the stomach floating preparation are volume and density.
A kind of low cellulose hydrocarbyl ether, polyacrylic acid or its pharmaceutical acceptable salt, oral long lasting drug formulations of medicine and effective dose foaming agent of containing of the 4th, 777, No. 033 U.S. Patent Publication of Supreme Being people company application.But the tablet made from said composition still has the major defect of described prior art, because the label of this system can not be kept perfectly in decomposition run.
The 4th, 844, No. 905 U.S. Patent Publication of outstanding person company application a kind of by pastille nuclear, the gas generation intermediate layer of forming by sodium carbonate and organic acid, and the granule skin of an expandable polymer film formation.But because the wriggling of gastric, the bubble of particle surface can not be permanent reservation, therefore particulate buoyancy continuous reduction, and because particle volume is too small, so can't guarantee to continue buoyant ability and flotation time, also just can't guarantee to stay the time that is not discharged from the stomach.
No. 63014715 Japanese patent publication of match Leah new drug Industrial Co., Ltd application a kind of slow releasing composition, said composition contains (A) high swelling degree hydrophilic polymer, preferably cellulose ether or polyvinyl alcohol, (B) insoluble polyvinylpolypyrrolidone, and (C) a kind of composition that can foam that contacts with gastric juice, preferably carbonate, particularly calcium carbonate or winnofil.It is promptly to release the medicine of form that this system does not comprise a part, and another part is the medicine of controlled release forms, does not possess for two stages to disengage mode.Therefore, when also not having medicine in the body at the beginning of taking medicine, the rate of releasing drug of this system is slower relatively than double speed medicine-releasing system.Another shortcoming is to have only high the expansion may meet the requirement of gastric retention with rapid expansible polymer, but we find several cellulose ethers commonly used to be arranged and do not meet this requirement.
The 5th, 651, No. 985 United States Patent (USP)s of Beyer Co., Ltd's application have proposed a kind of medicinal activity compositions, comprise a kind of polyvidone and sour medicine of being scattered in, and also comprise gas generation additive.The expansion rate of this system is slower, so that it can not reach required size and density in 30 minutes, can't realize continuing floating.In addition, technology is loaded down with trivial details and cost is higher.
The WO00/15198 PCT application of Lan Bakesai laboratory application relates to a kind of medical composition, comprises a kind of medicine, and a kind of gas produces compositions, a kind of extender, and a kind of thickening agent also can comprise a kind of gel formation polymer.Used gas producing agent is carbonate or bicarbonate.Extender is a polyvinylpolypyrrolidone, crosslinked light methylcellulose and carboxymethyl starch sodium.Thickening agent is a kind of carbohydrate natural gum that can improve viscosity rapidly.
The WO01/10419 Patent Cooperation Treaty international application of Lan Bakesai laboratory application relates to a kind of medical composition, comprise a kind of medicine, a kind of sugar, a kind of diluent and a kind of gas producing agent, the WO01/10405 Patent Cooperation Treaty international application that also is the application of Lan Bakesai laboratory relates to a kind of medical composition, comprises a kind of medicine, inert oil, a kind of sugar, a kind of diluent and a kind of gas producing agent.
The WO00/23045 Patent Cooperation Treaty international application of Sai Nuofei one Sheng Delabao application discloses and has a kind ofly comprised two or trilaminar medical composition, contains a kind of active medical components and changes its excipient that disengages and energy produces the system of carbon dioxide in the hydrophilic matrix of expanded polymer.In an embodiment, active component is in containing expanded polymer that layer as its excipient that disengages of change, and the second layer then contains expanded polymer and carbonate.Compositions is two-layer or trilaminar tablet.
The WO01/10417 Patent Cooperation Treaty international application of Jia Longni development company application discloses and proposes a kind of medical composition, comprise at least one contain active medical components and one or more excipient first mutually, and one be called as inactive second phase, comprises that at least a gas produces system and at least a hydrophilic polymer or porous mineral chemical compound; Wherein active at least 80% the active component that contains mutually.Use has limited less than 20% the rate of disengaging control excipient should obtain the formulation flexibility that the required rate of disengaging guarantees each situation of producing in batches of disengaging high level repeatability again.On the other hand, owing to want scrupulous to disengaging rate control with the selection of excipient, promptly use amount seldom also wants to guarantee the high repeatability of the situation of disengaging, so excipient high level expansion rapidly itself.System among the WO01/10417 adopts and nonactively realizes floatingly mutually, promptly reduce in the nonactive phase matrix by carbon dioxide is enclosed in that density realizes, but floating stability is not good.
At the gentamycin intra-gastric floating tablet of China listing, adopt octadecanol, acrylic resin, hydroxypropyl cellulose, the density of whole label is controlled at 1.1～1.2g/cm as label substrate 3Between, the major defect of said preparation is, the density of whole label is big, pressure is bigger to the floating ability influence of label, in release in vitro degree test, behind 15～30min just the swelling action by hydroxypropyl methylcellulose increase volume and form floatingly, and the label volumetric expansion is limited in one's ability, therefore in floating in stomach effect and unstable, be subjected to the influence of gastric environment bigger.
Above-mentioned existing gastric retention control medicine-releasing system, although can reach floating purpose, but all there is complex structure, uses the shortcoming that adjuvant is many, processing technique is loaded down with trivial details, cost is high, stability is not good, and the starting stage can not be floating immediately, reason is that initial density is bigger, volumetric expansion needs certain hour, and its floating ability (general with hold buoyancy represent) reduces along with the corrosion volume of label and reduces.
In addition, above-mentioned existing gastric retention control medicine-releasing system, its drug moiety is often made the form of ordinary preparation or common slow releasing preparation, but we find, much be fit to make the medicine of float type gastric retention control medicine-releasing system, when two stages of making are disengaged mode, be that a medicine part is the rapid release form, another part is slow release or controlled release forms, has more excellent effect in the clinical practice, as providing suitable initial drug concentration immediately at the initial stage of taking medicine, then keep more constant rate of releasing drug, can keep the blood drug level long-term stability.
Summary of the invention
For overcoming the shortcoming of existing gastric retention floating preparation, the invention provides a kind of new bladder-type stomach detention sustained and controlled release medicament delivery system, it is characterized in that comprising the hollow capsule that has been used to reduce the preparation global density, the outer watertight composition that can also wrap up macromolecular material and hydrophobic material composition of hollow capsule forms anti-water ballonet, the outer packaging medicine layer of capsule, described medicine layer can comprise medicament slow release layer or controlled release layer.Its characteristics are, because the capsule with hollow, greatly reduce the density of preparation integral body, and macromolecule filming material during whole release outside the capsule and hydrophobic material (as wax material) can effectively completely cut off gastric acid, avoid capsule to break or shape changes.On this basis, in the capsule a certain amount of gas-forming agent can also be housed, comprise carbonate and pharmaceutically acceptable organic acid, even if the capsule water inlet, buoyancy is constant thereby the gas that is produced still can be kept the assurance of capsule profile.Medicine and slow-release material hybrid packet are rolled in outside the capsule, are prepared into the medicament slow release layer, can obtain ideal slow release release effect, or after being wrapped in medicine layer outside the capsule,, can obtain ideal slow release release effect equally at medicine layer outer wrapping slow release layer; Medicine and excipient being wrapped in outside the capsule, making medicine layer, make controlled release layer at its outer wrapping clothing film, form medicated layer jointly, can obtain ideal zero-order release, is a kind of novel film controlling type controlled release stomach floating preparation.Compare with existing Entogastric lingering preparation, it is little and constant to have density, advantages such as drug release control ideal.And the present invention by utilizing ready-made extensively commercially available hungry area softgel shell to prepare air bag, has greatly simplified technology, has reduced cost very dexterously.
Stomach detention sustained and controlled release medicament releasing system of the present invention, comprise: (1) hollow capsule, outer wrapping macromolecule filming material and hydrophobic material are formed anti-water ballonet alternatively, also comprise the sealing coat of being made up of pharmaceutically acceptable excipient when needing, so that obtain continuously uniform medicated layer; (2) medicated layer that constitutes by medicine and pharmaceutically acceptable excipient, medicated layer is wrapped in outside the air bag, and described medicated layer comprises medicine controlled releasing layer or slow release layer.Described hollow capsule can be made of any pharmaceutically acceptable material, comprise hard capsule and soft capsule, wherein hard capsule comprises common stomach dissolution type and enteric coated capsule shell, can in gastro-intestinal Fluid, keep the complete of shape and preparation global density to be lower than gastro-intestinal Fluid for a long time, make the whole realization rapidly of preparation floating; Medicated layer can be earlier medicine and excipient to be wrapped in outside the air bag, and bundled slow-releasing material or medicine and the mixed with excipients that contains slow-release material are wrapped in air bag form slow release layer outward makes the stomach retention sustained-release drug release system again; Perhaps medicine and excipient being wrapped in air bag wraps up one deck clothing film outward then and makes controlled release layer, clothing film is made through film coating by pharmaceutically acceptable polymer, contain an amount of porogen in the film and meet water formation release micropore, the rate of release of control medicine, thus make the gastric retention controlled release medicament releasing system.If desired, also comprise release layer, form, be wrapped in outside slow release layer or the controlled release layer that form the medicine release layer, described excipient comprises adhesive, lubricant by medicine and excipient.In the air bag a certain amount of gas-forming agent can also be housed, comprise carbonate and pharmaceutically acceptable organic acid.The structure of bladder-type stomach detention sustained and controlled release medicament delivery system of the present invention is seen accompanying drawing 1,2,3.
Available hard capsule comprises common stomach dissolution type capsule, enteric coated capsule and insoluble capsule among the present invention, and its size is capsule from No. 000 to No. 7, and the capsule of special shape, can how much selecting according to drug dose and amount of excipient.
Can add a certain amount of gas-forming agent in the air bag that uses among the present invention, comprise carbonate and pharmaceutically acceptable organic acid, described carbonate comprises carbonate and bicarbonate, comprises sodium carbonate, sodium bicarbonate, magnesium carbonate etc., preferred sodium bicarbonate; Its consumption is 1%～20% of an air bag weight.Organic acid comprise medical acceptable organic acids such as citric acid, malic acid, succinic acid, tartaric acid, fumaric acid, maleic acid, ascorbic acid, glutamic acid, fumaric acid one or more, its consumption is 1%～20% of an air bag weight, is preferably 5%～10%.Gas-forming agent produces gas in a small amount of permeable back of air bag, to the air bag formation good supporting effect of deformation, avoids the character of air bag to change the flotation property that influences preparation.Use the air bag of the higher macromolecular material parcel of hydrophobicity, then can not add the gas propellant, also can keep the character of air bag in whole dispose procedure not change.
Hollow capsule described in the present invention is outer can to wrap up macromolecular material and hydrophobic material formation air sac water-proof layer, described macromolecular material can be one or more in ethyl cellulose, cellulose acetate, EudragitS, EudragitL, cellulose acetate phthalate (CAP), succinic acid acetic acid hydroxypropyl emthylcellulose (HPMCAS), Hydroxypropyl Methylcellulose Phathalate (HPMCP), the Opadry medicine macromolecular materials such as (OPADRY), its weightening finish is preferably 10%～30% for 5%～50% of air bag weight.
The hydrophobic material of the capsule outer wrapping described in the present invention comprises one or more of hexadecanol, stearic acid, brazil wax, white beeswax, hydrogenated castor wet goods material, and its weightening finish is preferably 10%～30% for 5%～50% of air bag weight.
When medicated layer medicine and the required weightening finish of excipient more after a little while, gap between employed capsular capsule body and the capsule cap can not be covered fully by the coating thing and form continuously medicated layer uniformly, need use pharmaceutically acceptable excipient earlier air bag to be carried out the contagion gown layer that coating forms continuously smooth before the parcel medicated layer this moment, carry out the medicated layer coating again, under the less situation of weightening finish, can form successive coatings, more help control drug release.The contagion gown layer is the extension of air sac water-proof layer, forms air bag jointly with watertight composition when needed.
The excipient that contagion gown layer described in the present invention uses comprises calcium hydrogen phosphate, starch, dextrin, sucrose, lactose, mannitol, hydroxypropyl cellulose, methylcellulose, in the pharmaceutically acceptable excipient such as sodium chloride, glucose, Pulvis Talci, titanium dioxide, Polyethylene Glycol, microcrystalline Cellulose, pregelatinized Starch one or more, its weightening finish is preferably 20%～40% for 10%～50% of air bag.
Gastric retention controlled release drug delivery system of the present invention, promptly being wrapped in the outer medicated layer of air bag is controlled release layer, the employed excipient of controlled release layer comprises adhesive, lubricant, penetration enhancer, cosolvent and clothing film.Wherein adhesive can be one or more in the medicine adhesive such as polyvidone, methylcellulose, ethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, hydroxypropyl methylcellulose, its consumption is 1%～50% of a medicine layer weight, is preferably 5%～30%; Employed lubricant can be one or more in magnesium stearate, Pulvis Talci, Polyethylene Glycol, stearic acid, sodium stearyl fumarate, zinc stearate, aluminium stearate, the hydrogenated castor wet goods pharmaceutical lubricant, its consumption is 1%～30% of a medicine layer, is preferably 3～20%; Penetration enhancer can be that low molecule saccharide is sucrose, sorbitol, mannitol, glucose, lactose, fructose; Inorganic salts is one or more of sodium chloride, potassium chloride, magnesium sulfate, potassium sulfate, sodium sulfate, and its consumption is 10%～80% of a medicine layer, is preferably 20～60%; Cosolvent can be one or more in the medicine cosolvents such as Polyethylene Glycol, tween 80, polyoxyethylene hydrogenated Oleum Ricini, sodium lauryl sulphate, beta-schardinger dextrin-, hydroxypropyl, its consumption is 10%～500% of a drug weight, is preferably 100%～200%.Clothing film comprises macromolecular material, plasticizer, porogen etc., the weightening finish of clothing film is 1%～40% of whole preparation, wherein employed macromolecular material can be one or more of medicine macromolecular materials such as cellulose acetate, ethyl cellulose, crylic acid resin, cellulose acetate acetate, hydroxypropyl methylcellulose acetate, polyvinyl alcohol, consumption accounts for 20%～90% of clothing film, is preferably 50%～80%; Employed plasticizer can be a glycerol, one or more of plasticizers such as propylene glycol, Polyethylene Glycol, triethyl citrate, phthalic acid ester, and consumption accounts for 5%～40% of clothing film, is preferably 10%～30%.Porogen can be one or more in the solable matters such as glycerol, propylene glycol, Polyethylene Glycol, sucrose, mannitol, lactose, sodium chloride, hydroxypropyl cellulose, methylcellulose, hydroxypropyl methylcellulose, polyvidone, consumption accounts for 5%～40% of clothing film, be preferably 10%～30%, thereby constitute the floating controlled release preparation of micropore permeation pump type air sac stomach, structure is seen accompanying drawing 1.
Stomach retention sustained-release drug release system of the present invention, promptly being wrapped in the outer medicated layer of air bag is slow release layer, can realize by dual mode: 1) medicine and excipient can be wrapped on the air bag, form medicine layer, the bundled slow-releasing material forms slow release layer then, constitutes the floating film controlling type slow releasing preparation of air sac stomach; 2) with medicine and slow-release material and other mixed with excipients, be wrapped in the outer pastille slow-release layer that directly forms of air bag, constitute the floating skeleton type sustained release preparation of air sac stomach.Above-mentioned two kinds of structures are referring to accompanying drawing 2,3.The excipient that slow release layer uses comprises slow-release material, adhesive, lubricant, penetration enhancer, cosolvent.Use therein slow-release material can be one or more in hydroxypropyl methylcellulose, polyoxyethylene, ethyl cellulose, hydroxypropyl cellulose, crylic acid resin, stearic acid, brazil wax, the hydrogenated castor wet goods medicament slow release material, consumption accounts for 10%～70% of slow release layer, is preferably 20%～50%; The adhesive that uses can be one or more in the medicine adhesive such as polyvidone, methylcellulose, ethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, hydroxypropyl methylcellulose, and its consumption is 5%～30% of a slow release layer; The lubricant that uses can be one or more in magnesium stearate, Pulvis Talci, Polyethylene Glycol, stearic acid, sodium stearyl fumarate, zinc stearate, aluminium stearate, the hydrogenated castor wet goods pharmaceutical lubricant, its consumption is 1%～20% of a slow release layer weight, is preferably 2～15%; The penetration enhancer that uses can be that low molecule saccharide is sucrose, sorbitol, mannitol, glucose, lactose, fructose; Inorganic salts is one or more of sodium chloride, potassium chloride, magnesium sulfate, potassium sulfate, sodium sulfate, and its consumption is 5%～50% of a slow release layer weight, is preferably 10～30%; The cosolvent that uses can be one or more in the medicine cosolvents such as Polyethylene Glycol, tween 80, polyoxyethylene hydrogenated Oleum Ricini, sodium lauryl sulphate, beta-schardinger dextrin-, hydroxypropyl, its consumption is 10%～500% of a drug weight, is preferably 100%～200%.Slow release layer can also add gas-forming agent, comprises carbonate, preferred sodium carbonate, sodium bicarbonate, magnesium carbonate, and its consumption is 1%～20% of a slow release layer weight.After oral, meet hydrochloric acid under one's belt and in sustained-release matrix, produce gas, further reduce whole medicine-releasing system density.
Stomach detention sustained and controlled release medicament releasing system of the present invention if desired, also contains release layer, is made up of medicine and excipient, is wrapped in outside slow release layer or the controlled release layer, forms the medicine release layer, thereby makes two stomach detention sustained and controlled release medicament releasing systems of releasing.Described excipient comprises adhesive, lubricant.Adhesive can be one or more in the medicine adhesive such as polyvidone, methylcellulose, ethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, hydroxypropyl methylcellulose, and its consumption is 5%～30% of a rapid release coatings.Lubricant can be one or more in magnesium stearate, Pulvis Talci, Polyethylene Glycol, stearic acid, sodium stearyl fumarate, zinc stearate, aluminium stearate, the hydrogenated castor wet goods pharmaceutical lubricant, and its consumption is 1%～30% of a rapid release coatings weight.
Be suitable for the medicine of stomach detention sustained and controlled release medicament releasing system of the present invention, comprise all suitable medicines of making the Entogastric lingering preparation, specifically comprise: the gastric antiacids that 1) plays a role under one's belt; 2) medicine that mainly absorbs from stomach is as weak organic acid class medicine; 3) degree of dissolving in the stomach is greater than the medicine of dissolubility in intestinal; 4) medicine of particular requirement clinically, as be wrapped with the stomach floating preparation of anhydrous citric acid and sodium bicarbonate effervescent, be used for the few patients with gastric cancer of gastric acid secretion; 5) absorb short medicine of relatively poor or non-absorbent half-life for the gastrointestinal tract hypomere, be prepared into the stomach floating preparation, realize being administered once in 1st.
The medicine that can be used for stomach detention sustained and controlled release medicament releasing system of the present invention can be selected from following medicine, and promptly hangover medicine is treated the dementia medicine, anesthetics, acromegaly curative, analgesic, the treating asthma medicine, anticarcinogen, anticoagulant, antithrombotic, antiepileptic, medicine for treating diabetes, Bendectin, glaucoma treatment medicine, antihistaminic, anti-medicine, Parkinson's disease curative, the platelet curative of infecting, antirheumatic, spasmolytic and cholinergic drug, cough medicine, carbonic anhydrase inhibitors, the cardiovascular treatment medicine, cholinesterase inhibitor, nervus centralis disorder treatment medicine, central nervous excitation agent, contraceptive, the Cystic fibrosis curative, dopamine receptor gaonist, endometritis curative, the erection problem curative, the infertility treatment medicine, gastrointestinal drug, immunomodulator, immunosuppressant, the memory reinforcing medicine, migraine preparation, loosening all muscles medicine, the nucleoside analogues chemical compound, the osteoporosis therapy medicine is intended the parasympathetic nervous curative, prostaglandin, Psychotropic drug, calm, hypnosis and neuroleptic agent, treating skin disease medicine, steroid and hormone.
The preparation method of stomach detention sustained and controlled release medicament releasing system of the present invention is as follows:
(1) air bag adopts two stage coatings in conjunction with heat-sealable technology, makes the seal of air bag reach designing requirement, has effectively stoped entering of moisture content, and bladder shape is remained unchanged.Concrete grammar is as follows: the mixing coating solution with macromolecular material and hydrophobic material carries out coating to not locked capsule shells, stop coating when increasing weight to 20%～70% left and right sides that coating is estimated total augment weight, preferred 30%, after the intensive drying, capsule is locked, carry out the coating of remainder 30%～80% again, after coating is finished, placed 12～24 hours down for 45 ℃, heat-sealable, make complete air bag.Test shows, this air bag are rotated 6h at 37 ℃ among the 0.1N HCl, and air bag still is kept perfectly, and do not have obvious ruckbildung, and the watertight composition total augment weight is 10%～80% of a capsules weight, is preferably 20%～60%.
(2) use ordinary coating technology or centrifugal granulating technology to prepare medicated layer, to be medicine and excipient wrap up the outer wrapping slow-release material by coating with the air bag core again forms slow release layer or medicine is wrapped in air bag with the mixed with excipients that contains slow-release material and form slow release layer outward, makes the stomach retention sustained-release drug release system; Perhaps medicine and excipient are wrapped in air bag and wrap up one deck clothing film outward then and make controlled release layer, clothing film is made through film coating by pharmaceutically acceptable polymer, contain an amount of porogen in the film and meet water formation release micropore, the rate of release of control medicine, thus make the gastric retention controlled release medicament releasing system.
(3) preparation is two if desired releases stomach detention sustained and controlled release medicament releasing system, can use ordinary coating technology or centrifugal granulating technology to prepare release layer, and medicine and excipient such as adhesive, lubricant are wrapped in outside slow release or the controlled release layer, forms the immediate release drug layer.Concrete operations can be carried out according to the requirement of the packaging technique in the existing known technology by those skilled in the art, and the kind of used excipient and consumption can carry out according to above-mentioned explanation.
In the above-mentioned steps (1), for the less medicine of specification, the required weightening finish of medicated layer medicine and excipient is generally less, the capsule body of the capsule shells of using and the gap between the capsule cap can not be covered fully by the coating thing and form continuously medicated layer uniformly, need use pharmaceutically acceptable excipient earlier air bag to be wrapped to form the contagion gown layer of continuously smooth before the parcel medicated layer this moment, carry out the medicated layer coating again, can be under the less situation of weightening finish, can form successive drug coating layer, more help control drug release.The contagion gown layer is the extension of air sac water-proof layer, forms air bag jointly with watertight composition when needed.Its weightening finish is preferably 15%～35% for 10%～40% of air bag.
And when medicated layer medicine and the required weightening finish of excipient are big, can be with enteric capsule shell directly as hollow capsule, need not to wrap up the watertight composition of forming by macromolecule filming material, hydrophobic material, directly wrap up medicated layer, when the medicine layer weightening finish arrives certain value, can obtain the medicine layer of continuously smooth, bundled slow-releasing layer or clothing film can obtain gastric retention type release preparation again.
Compare with existing stomach floating preparation described in the background technology, the invention has the advantages that:
1) adopted hollow gasbag, can effectively reduce the density of whole preparation, the average density of whole preparation generally can be controlled at 0.6g/cm 3Below, obviously be better than the stomach floating preparation that gone on the market at present, can add gas-forming agent in the air bag in addition, the gas of generation can make air bag effectively expand, and forms suitable size when further reducing the density of preparation, reduces the probability that stomach is discharged;
2) starting stage can be floating immediately, holds buoyancy continuous and constant.Because air bag is airtight relatively, gas is difficult for scattering and disappearing; The air bag that adds gas-forming agent is in addition met water generates gas, and gas wraps in the air bag, can not overflow because of gastric peristalsis makes gas, causes floating ability to change;
3) adopt slow release or controlled release coat, in effective sustained release speed, can significantly not increase the weight and volume of whole preparation again, more help packing and transportation and the patient medicine of swallowing;
4) under the situation of needs, adopt slow controlled release layer to wrap up release layer outward again, can realize the double speed release, promptly provide suitable initial drug concentration at the initial stage of taking medicine, then keep more constant rate of releasing drug, thereby keep blood drug level stable;
5) preparation is originally as the slow/controlled release preparation, after being expelled to small intestinal, stomach still can keep stable rate of releasing drug, absorb relatively poor medicine for colon and can effectively prolong time of staying, realize that 24h is administered once, improved the compliance that the patient takes medicine greatly at absorption site;
6) gas expansion generation extrapolability is constant in the air bag, can effectively promote the release of insoluble drug, avoids medicine residual bioavailability that causes in preparation on the low side.
7) preparation method is simple, uses the sophisticated packaging technique of industry to prepare, and cost is low, is easy to suitability for industrialized production.
Moreover a particular object of the present invention provides gentamycin, rosiglitazone, ondansetron or ranitidine and reaches the bladder-type stomach detention sustained and controlled release medicament releasing system of pharmaceutical acceptable salt separately.
Rosiglitazone is a second filial generation thiazolidinediones blood sugar lowering new drug, mainly brings into play drug effect by increasing insulin sensitivity, is used for the treatment of the type diabetes, and commonly used is its maleate and tartrate.The rosiglitazone intra-gastric floating tablet of existing bibliographical information adopts the technology of preparing of traditional intra-gastric floating tablet agent, select full-bodied hydrophilic gel material hydroxypropyl methylcellulose (HPMC) for use, add an amount of foaming agent simultaneously, adopt direct compression of full-powder, make rosiglitazone Entogastric lingering slow releasing tablet, claim to have the bioavailability identical with the conventional tablet multiple dose administration.But, utilize isotope scitiphotograph technology that the delay situation of this intragastric floating tablets in human stomach verified, the result shows, this stomach floating preparation can not be floating immediately in the starting stage of taking medicine, reason is that initial density is bigger, volumetric expansion needs certain hour, and reduces along with the corrosion volume of label after its floating ability and reduce then and discharged by stomach.Ours studies show that in addition, the dissolubility of rosiglitazone in simulated gastric fluid is about more than 10,000 times of simulated intestinal fluid, when this prompting enters intestinal neutrality or alkaline environment when common slow releasing tablet or intra-gastric floating tablet in case by the stomach discharge, will cause the reduction of medicine stripping and absorption, cause the bioavailability that can't reach identical with ordinary preparation.The present invention adopts the bladder-type floating preparation can guarantee that the density of preparation is less relatively (general＜0.6g/cm 3), be floatability at the initial stage of taking medicine, because air bag at the gastric dimensionally stable, keeps relative stability the volume of whole preparation, thereby keep floating ability stable and that continue.Bladder-type stomach floating preparation according to embodiment 3 preparations, carry out begle dog single-dose, the result shows that the blood drug level of stomach floating preparation of the present invention is more steady, bioavailability and ordinary preparation do not have significant difference, and common slow releasing preparation bioavailability is starkly lower than ordinary preparation and floating preparation.Hold the buoyancy result and show, it is stable that the floating preparation of using this technical scheme preparation is held buoyancy.Extracorporeal releasing test shows that floating preparation all presents floating state in the whole release stage, and release profiles shows that control release type is zero level and discharges the spacetabs type Higuchi equation.At whole deenergized period, stomach floating preparation profile of the present invention is kept perfectly.
Gentamycin sulfate is an aminoglycosides antibiotics, and helicobacter pylori is had inhibitory action, has been widely used in clinically in recent years, is used for gastritis, duodenal ulcer, and has obtained comparatively satisfied curative effect.Because gentamycin sulfate is the local action medicine, the local concentration in stomach and duodenum and its antiphlogistic effects of appreciable impact action time.At present existing gentamycin intra-gastric floating tablet listing has adopted hydroxypropyl methylcellulose and acrylic resin and octadecanol as substrate, leans on autologous density and water-swellable at floating in stomach, and the heavily about 300mg of sheet adopts the 10mm stamping, and its density is 1.1～1.2g/cm 3Between, its density of pressure appreciable impact and the expansion time of label, float the time thereby influence to rise in its body.Extracorporeal releasing experiment shows that this intra-gastric floating tablet could be realized floating by the gel swelling effect more than the 30min in release medium, and because global density is bigger, can't keep the stable showy ability that continues.Use the bladder-type stomach floating preparation of the present invention's preparation, its density is all less than 0.6g/cm 3, in the release in vitro medium, rise immediately and float, and entering along with moisture in the air bag, gas-forming agent is met the water generates bubble, makes volumes of formulation continue to expand, and density further reduces, and owing to adopt the film control techniques, preparation profile in dispose procedure is kept perfectly, and holding buoyancy increases steadily.
Ondansetron is a kind of 5-hydroxy tryptamine 3 (5-HT3) receptor antagonist of high selectivity, it is a kind of new potent Bendectin, the mechanism of this medicine control nausea and vomiting, be antagonism periphery and axoneuron 5-HT3 receptor, thereby blocking-up discharges because of factors such as chemotherapy and radiation cause the 5-hydroxy tryptamine of small intestinal, causes that by the 5-HT3 receptor fan walks the excited vomiting reflex that causes of nervus centripetalis.This product tool efficient selective effect, thereby do not have the side effect of other Bendectins is as The extrapyramidal symptoms, excessively calmness etc., clinical its hydrochlorate commonly used.Ondansetron is made Gastroretentive formulations, and effectively prolong drug improves bioavailability in the gastrointestinal tract holdup time.
Ranitidine hydrochloride (ranitidine hydrochloride) is that present clinical practice is more extensive, and curative effect is H preferably 2Receptor antagonist is mainly used in treatment duodenal ulcer, benign gastric ulcer, postoperative ulcer, reflux esophagitis etc., has strong drug action, act on characteristics rapidly, but because this medicine is eliminated very fast (t in vivo 1/2=2～2.2h), it is more that ordinary preparation day is obeyed number of times, and the blood concentration fluctuation amplitude is bigger, administration inconvenience.Because ranitidine hydrochloride is relatively poor to the hypomere absorption in the small intestinal stage casing, therefore the bioavailability of ordinary preparation is better than common slow releasing preparation, be made into the gastric retention type sustained-release preparation, both effectively prolong drug in the time of staying of absorption site, all right effectively control drug release speed, keep blood drug level steadily and lasting, minimizing medication number of times improves patient's compliance.
The above-mentioned bladder-type slow/controlled release stomach floating preparation of the present invention has possessed essential two key factors of stomach floating preparation:
1. global density is little, and the density of bladder-type slow/controlled release preparation is all less than 0.6g/cm 3
2. volumes of formulation is appropriate in vivo is expanded to the globoid that the line of apsides is 0.5x0.8cm to 0.7x2.0cm, compares with the microcapsule of prior art, and size is bigger, studies show that, the effect that hinders gastric emptying is obviously better, and the holdup time of gastric is obviously longer.
3. holding buoyancy is the important indicator of estimating the stomach floating preparation, the appreciable impact preparation is in the floating character of gastric, so prescription of our preparation, use the buoyancy analyzer of holding shown in the accompanying drawing 4 to carry out holding the buoyancy test, the result shows, it is stable that the gastric retention shape preparation of embodiment preparation is held buoyancy, and preparation is in floating state for a long time.
4, owing to adopted the air bag of capsule preparation, its shape helps the patient swallows, and has increased patient's the compliance of taking medicine.
5, release the effect that stomach floating preparation that stomach detention sustained and controlled release medicament releasing system makes can reach gentle two kinds of dosage combination medications of the controlled release output of quick releasing formulation by two, the initial stage of promptly taking medicine reaches effective blood drug concentration rapidly, blood drug level held stationary then, realize that blood drug level remains in the effective blood drug concentration scope for a long time, avoided the slow releasing preparation onset slow, quick releasing formulation short shortcoming action time effectively reduces blood concentration fluctuation, has guaranteed that fully safety of medicine is effective.
6, the floating dynamic test result of stomach shows, bladder-type stomach floating preparation is 5h at the mean residence time of gastric, and the gastric mean residence time (1.5h) much larger than the ordinary preparation of bibliographical information has reached the designing requirement of stomach floating preparation fully.
Description of drawings:
The floating controlled release preparation sketch map of Fig. 1 micropore permeation pump type air sac stomach
The floating skeleton slow releasing preparation of Fig. 2 air sac stomach sketch map
The floating film controlling type slow releasing preparation of Fig. 3 air sac stomach sketch map
Fig. 4 holds the buoyancy determinator
Fig. 5 embodiment 1 Tartraric rosiglitazone stomach retention sustained-release sheet release profiles
The stomach detention sustained release formulation release profiles of Fig. 6 embodiment 2 rosiglitazone maleate
Fig. 7 embodiment 3 rosiglitazone maleate gastric retention controlled release preparation release profiles
Fig. 8 embodiment 4 Tartraric rosiglitazone gastric retention controlled release preparation release profiles
Fig. 9 embodiment 5 Tartraric rosiglitazone gastric retention controlled release preparation release profiles
Figure 10 embodiment 6 rosiglitazone maleate gastric retention controlled release preparation release profiles
Figure 11 embodiment 7 Tartraric rosiglitazone gastric retention controlled release preparation release profiles
Figure 12 embodiment 8 gentamycin sulfate gastric retention controlled release preparation release profiles
Figure 13 embodiment 9 gentamycin sulfate gastric retention controlled release preparation release profiles
The stomach detention sustained release formulation release profiles of Figure 14 embodiment 10 gentamycin sulfate
The stomach detention sustained release formulation release profiles of Figure 15 embodiment 11 gentamycin sulfate
Figure 16 embodiment 12 gentamycin sulfate gastric retention rapid release/slow releasing preparation release profiles
Figure 17 embodiment 13 gentamycin sulfate gastric retention rapid release/controlled release preparation release profiles
The stomach detention sustained release formulation release profiles of Figure 18 embodiment 14 Ondansetron Hydrochloride
Figure 19 embodiment 15 Ondansetron Hydrochloride gastric retention controlled release preparation release profiles
Figure 20 embodiment 16 Ondansetron Hydrochloride gastric retention controlled release preparation release profiles
Figure 21 embodiment 17 Ondansetron Hydrochloride gastric retention controlled release preparation release profiles
Figure 22 embodiment 18 Ondansetron Hydrochloride gastric retention controlled release preparation release profiles
Figure 23 embodiment 19 ranitidine hydrochloride gastric retention rapid release/controlled release preparation release profiles
The stomach detention sustained release formulation release profiles of Figure 24 embodiment 20 ranitidine hydrochloride
Figure 25 embodiment 21 ranitidine hydrochloride gastric retention controlled release preparation release profiles
Figure 26 embodiment 22 ranitidine hydrochloride gastric retention rapid release/slow releasing preparation release profiles
Figure 27 embodiment 23 ranitidine hydrochloride gastric retention controlled release preparation release profiles
Figure 28 embodiment 24 ranitidine hydrochloride gastric retention rapid release/controlled release preparation release profiles
Figure 29 embodiment 25 rosiglitazone maleate gastric retention controlled release preparation release profiles
Figure 30 embodiment 26 rosiglitazone maleate gastric retention controlled release preparation release profiles
Curve during the floating controlled release preparation Begle of Figure 31 rosiglitazone maleate stomach dog medicine
Curve (n=6) during Figure 32 ranitidine hydrochloride gastric floating slow-release preparation Begle dog medicine
The floating kinetics stomach of Figure 33 embodiment 27 stomaches is according to shadow X-ray sheet
The stomach detention sustained release formulation release profiles of Figure 34 embodiment 28 gentamycin sulfate
The specific embodiment
Following examples only are used for proving the feasibility of technical scheme of the present invention, and in principle, according to the present invention, any suitable medicine of making the floating in stomach preparation all can be made the floating slow/controlled release preparation of bladder-type stomach with reference to following method.
Embodiment 1
Air bag is formed: slow release layer is formed:
1000 Tartraric rosiglitazone 8g of No. 1 capsule
Ethyl cellulose 9.0g stearic acid 32g
Stearic acid 15.0g ethyl cellulose 40g
Triethyl citrate 4.5g polyvidone k30 16g
Pulvis Talci 3.0gPolyethylene Glycol 24g
Dehydrated alcohol adds to 300ml Pulvis Talci 16g
90% alcoholic solution adds to 1000ml
Technology: No. 1 capsule shells is put into coating pan, the sheet bed tempertaure sprays into the waterproof coating solution (being made in dehydrated alcohol by stearic acid, ethyl cellulose, triethyl citrate, Pulvis Talci dissolution) for preparing for 45 ℃, after the coating weightening finish 15%, capsule is locked, the coating weightening finish 15% again, place 12h down, promptly get and prevent water ballonet for 45 ℃; With Tartraric rosiglitazone, stearic acid, ethyl cellulose, polyvidone, Polyethylene Glycol, Pulvis Talci dissolution in ethanol solution, be mixed with the slow release layer coating solution, the air bag for preparing is put into coating pan, adopt conventional film coating method at the outer bundled slow-releasing layer of air bag, calculate the coating weightening finish with the rosiglitazone amount, every capsules contains rosiglitazone 8mg, promptly gets Tartraric rosiglitazone air sac stomach float slow release preparation.Gastroretentive formulations is fixed on the spring top of holding the buoyancy analyzer shown in the accompanying drawing 4, puts into and measure cup, add 0.1N hydrochloric acid, the record preparation is suspended in the position of measuring cup, every 1 hour record once, and to 12 hours.The result shows, the buoyancy of holding of the floating shape preparation of stomach of present embodiment preparation does not reduce in 12 hours.Release test is measured according to 2005 editions one drug release determination first method of Chinese Pharmacopoeia (appendix C), is dissolution medium with the hydrochloric acid 900ml of 0.1mol/L, and temperature is (37 ± 0.5) ℃, rotating speed is under the 100r/min condition, operation in accordance with the law, timing when white running begins is respectively at 0.5,1,2,4,6, the 8h sampling and measuring, the cumulative release curve as shown in Figure 5.
Embodiment 2
Air bag is formed: medicine layer:
1000 rosiglitazone maleate 1.5g of No. 1 capsule
Ethyl cellulose 9.0g Eudragit RL100 4.5g
Stearic acid 15.0g ethyl cellulose 2.0g
Triethyl citrate 4.5g Polyethylene Glycol 1.0g
Pulvis Talci 3.0g90% alcoholic solution 100ml
Dehydrated alcohol adds to 300ml
Sealing coat: clothing film:
Lactose 30g Eudragit RS100 2.5g
Polyvidone k30 3.0gEthyl cellulose 2.0g
Dehydrated alcohol 200ml Polyethylene Glycol 1.0g
Triethyl citrate 0.8g
90% ethanol 100ml
Technology: No. 1 capsule shells is put into coating pan, the sheet bed tempertaure sprays into the waterproof coating solution (being made in dehydrated alcohol by stearic acid, ethyl cellulose, triethyl citrate, Pulvis Talci dissolution) for preparing for 45 ℃, after the coating weightening finish 15%, capsule is locked, the coating weightening finish 20% again, place 12h down, promptly get and prevent water ballonet for 45 ℃; Lactose is scattered in the ethanol solution of polyvidone k30 and makes sealing coat coating suspension, the air bag for preparing is put into coating pan, adopt conventional film coating method in the outer parcel of air bag sealing coat, coating weightening finish 25%; Rosiglitazone maleate, EudragitRL100, ethyl cellulose, Polyethylene Glycol are dissolved in 90% alcoholic solution, be mixed with the medicated layer coating solution, the air bag for preparing is put into coating pan, adopt conventional film coating method in the outer parcel of air bag medicated layer, calculate the coating weightening finish with the rosiglitazone amount, every capsules contains rosiglitazone 8mg; Eugragit RS100, ethyl cellulose, Polyethylene Glycol and triethyl citrate be dissolved in make the clothing film coating solution in 90% alcoholic solution, adopt conventional film coating method in the outer parcel of pastille air bag clothing film, coating weightening finish 18%～20%.Gastroretentive formulations is fixed on the spring top of holding the buoyancy analyzer shown in the accompanying drawing 4, puts into and measure cup, add 0.1N hydrochloric acid, the record preparation is suspended in the position of measuring cup, every 1 hour record once, and to 12 hours.The result shows, the buoyancy of holding of the floating shape preparation of stomach of present embodiment preparation does not reduce in 12 hours.The release test is measured according to 2005 editions one drug release determination first method of Chinese Pharmacopoeia (appendix C), hydrochloric acid 900ml with 0.1mol/L is a dissolution medium, temperature is (37 ± 0.5) ℃, and rotating speed is under the 100r/min condition, in accordance with the law operation, timing when the running beginning, respectively at 1,2,4, the 6h sampling and measuring, the cumulative release curve as shown in Figure 6.
Embodiment 3
Air bag is formed Eudragit RL100 4.5g
Watertight composition: ethyl cellulose 2.0g
Eudragit L100 9.0g Polyethylene Glycol 1.0g
Stearic acid 15.0g 90% alcoholic solution 100ml
Triethyl citrate 4.5g
Pulvis Talci 3.0gClothing film:
Dehydrated alcohol adds to 300ml Eudragit RS100 2.5g
Ethyl cellulose 2.0g
Medicated layer is formed: Polyethylene Glycol 1.0g
Medicine layer: Triethyl citrate 0.8g
Rosiglitazone maleate 1.5g 90% ethanol 100ml
Technology: No. 1 capsule shells is put into coating pan, the sheet bed tempertaure sprays into the waterproof coating solution (being made in dehydrated alcohol by stearic acid, Eudragit L100, triethyl citrate, Pulvis Talci dissolution) for preparing for 45 ℃, after the coating weightening finish 15%, capsule is locked, the coating weightening finish 15% again, place 12h down, promptly get and prevent water ballonet for 45 ℃; Rosiglitazone maleate, EudragitRL100, ethyl cellulose, Polyethylene Glycol are dissolved in 90% alcoholic solution, be mixed with the medicated layer coating solution, the air bag for preparing is put into coating pan, adopt conventional film coating method in the outer parcel of air bag medicated layer, calculate the coating weightening finish with the rosiglitazone amount, every capsules contains rosiglitazone 8mg; Eugragit RS100, ethyl cellulose, Polyethylene Glycol and triethyl citrate be dissolved in make the clothing film coating solution in 90% alcoholic solution, adopt conventional film coating method in the outer parcel of pastille air bag clothing film, coating weightening finish 24%～26%.Gastroretentive formulations is fixed on the spring top of holding the buoyancy analyzer shown in the accompanying drawing 4, puts into and measure cup, add 0.1N hydrochloric acid, the record preparation is suspended in the position of measuring cup, every 1 hour record once, and to 12 hours.The result shows, the buoyancy of holding of the floating shape preparation of stomach of present embodiment preparation does not reduce in 12 hours.The release test is measured according to 2005 editions one drug release determination first method of Chinese Pharmacopoeia (appendix C), hydrochloric acid 900ml with 0.1mol/L is a dissolution medium, temperature is (37 ± 0.5) ℃, and rotating speed is under the 100r/min condition, in accordance with the law operation, timing when the running beginning, respectively at 1,2,4, the 6h sampling and measuring, the cumulative release curve as shown in Figure 7.
Embodiment 4
Air bag is formed:
1000 of No. 1 capsules
NaHCO 3 7.5g
Citric acid 12.5g
Eudragit?RS 20g
Pulvis Talci 8g
Triethyl citrate 10g
Dehydrated alcohol adds to 250ml
Slow release layer is formed:
Tartraric rosiglitazone 8g
Ethyl cellulose 40g
Polyvidone k30 12g
Brazil wax 15g
Lactose 10g
Pulvis Talci 5g
Dehydrated alcohol adds to 400ml
Technology: sodium bicarbonate and citric acid are packed in No. 1 capsule shells, put into coating pan, the sheet bed tempertaure sprays into the waterproof coating solution (being made in dehydrated alcohol by EudragitRS and triethyl citrate, Pulvis Talci dissolution) for preparing for 45 ℃, coating weightening finish 15%, taking-up with capsule locked after, the coating weightening finish is placed 24h down for 15%, 45 ℃ again; With Tartraric rosiglitazone, ethyl cellulose, brazil wax, lactose, polyvidone k30 dissolving are scattered in the dehydrated alcohol, are mixed with the slow release layer coating solution, and the air bag for preparing is put into coating pan, adopt conventional film coating method at the outer bundled slow-releasing layer of air bag, calculate the coating weightening finish with the rosiglitazone amount, every capsules contains rosiglitazone 8mg, promptly gets Tartraric rosiglitazone air sac stomach float slow release preparation.Measure according to the described method of embodiment 1 and to hold buoyancy, the result shows, the buoyancy of holding of the floating shape preparation of stomach of present embodiment preparation does not reduce in 12 hours.Release test is measured according to 2005 editions one drug release determination first method of Chinese Pharmacopoeia (appendix C), is dissolution medium with the hydrochloric acid 900ml of 0.1mol/L, and temperature is (37 ± 0.5) ℃, rotating speed is under the 100r/min condition, operation in accordance with the law, timing when running begins certainly is respectively at 0.5,1,2,4,6, the 8h sampling and measuring, the cumulative release curve as shown in Figure 8.
Embodiment 5
Air bag is formed:
1000 of No. 1 capsules
Ethyl cellulose 9.0g
Stearic acid 15.0g
Triethyl citrate 4.5g
Pulvis Talci 3.0g
Dehydrated alcohol adds to 300ml
Medicine layer is formed: clothing film is formed:
Tartraric rosiglitazone 8g ethyl cellulose 12g
Polyvidone k30 3g Macrogol 4000 1.5g
Mannitol 20g HPMC 1.5g
Polyethylene Glycol 5g Diethyl phthalate 1.5ml
Pulvis Talci 3g80% alcoholic solution adds to 400ml
30% ethanol adds to 200ml
Technology: No. 1 capsule shells is put into coating pan, the sheet bed tempertaure sprays into the waterproof coating solution (being made in dehydrated alcohol by stearic acid, ethyl cellulose, triethyl citrate, Pulvis Talci dissolution) for preparing for 45 ℃, after the coating weightening finish 15%, capsule is locked, the coating weightening finish 15% again, place 12h down, promptly get and prevent water ballonet for 45 ℃; With Tartraric rosiglitazone, mannitol, Polyethylene Glycol, polyvidone k30 are dissolved in 30% alcoholic solution, be mixed with the medicine layer coating solution, the air bag for preparing is put into coating pan, adopt conventional film coating method at the outer packaging medicine layer of air bag, calculate the coating weightening finish with the rosiglitazone amount, every capsules contains rosiglitazone 8mg, adopt the identical operations method that the controlled release layer coating solution for preparing is wrapped on the pastille air bag, form clothing film, coating weightening finish 10%, place 24h under 45 ℃ of conditions, promptly get the floating controlled release preparation of Tartraric rosiglitazone air sac stomach.Measure according to the described method of embodiment 1 and to hold buoyancy, the result shows, the buoyancy of holding of the stomach floating preparation of present embodiment preparation does not reduce in 12 hours.Release test is measured according to 2005 editions one drug release determination first method of Chinese Pharmacopoeia (appendix C), is dissolution medium with the hydrochloric acid 900ml of 0.1mol/L, and temperature is (37 ± 0.5) ℃, rotating speed is under the 100r/min condition, operation in accordance with the law, timing when running begins certainly is respectively at 0.5,1,2,4,6, the 8h sampling and measuring, the cumulative release curve as shown in Figure 9.Carry out the test of begle dog single-dose, the results are shown in accompanying drawing 20, the blood drug level that shows stomach floating preparation of the present invention is more steady, and bioavailability and ordinary preparation do not have significant difference, and common slow releasing preparation bioavailability is starkly lower than ordinary preparation and floating preparation.
Embodiment 6
Air bag is formed:
1000 of No. 1 capsules
Ethyl cellulose 6.0g
Stearic acid 2.0g
EudragitL 10.0g
Triethyl citrate 4.5g
Pulvis Talci 3.0g
Dehydrated alcohol adds to 300ml
Medicine layer is formed: clothing film is formed:
Rosiglitazone maleate 8g ethyl cellulose 12g
Polyvidone k30 3g Macrogol 4000 4g
Mannitol 20g HPMC 2g
Polyethylene Glycol 5g Diethyl phthalate 1.5ml
Pulvis Talci 3g80% alcoholic solution adds to 400ml
30% ethanol adds to 200ml
Technology: No. 1 capsule shells is put into coating pan, the sheet bed tempertaure sprays into the waterproof coating solution (being made in dehydrated alcohol by EudragitL, stearic acid, ethyl cellulose, triethyl citrate, Pulvis Talci dissolution) for preparing for 45 ℃, after the coating weightening finish 15%, capsule is locked, the coating weightening finish 15% again, place 12h down, promptly get anti-water ballonet for 45 ℃ with enteric properties; With rosiglitazone maleate, mannitol, Polyethylene Glycol, polyvidone k30 is dissolved in 30% alcoholic solution, be mixed with the medicine layer coating solution, the air bag for preparing is put into coating pan, adopt conventional film coating method at the outer packaging medicine layer of air bag, calculate the coating weightening finish with the rosiglitazone amount, every capsules contains rosiglitazone 8mg, adopt the identical operations method that the controlled release layer coating solution for preparing is wrapped on the pastille air bag, form clothing film, coating weightening finish 18%～20%, place 24h under 45 ℃ of conditions, promptly get the floating controlled release preparation of rosiglitazone maleate air sac stomach.Measure according to the described method of embodiment 1 and to hold buoyancy, the result shows, the buoyancy of holding of the stomach floating preparation of present embodiment preparation does not reduce in 12 hours.The release test is measured according to 2005 editions one drug release determination first method of Chinese Pharmacopoeia (appendix C), hydrochloric acid 900ml with 0.1mol/L is a dissolution medium, temperature is (37 ± 0.5) ℃, and rotating speed is under the 100r/min condition, in accordance with the law operation, timing when white running begins, respectively at 1,2,4, the 6h sampling and measuring, the cumulative release curve as shown in Figure 10
Embodiment 7
Air bag is formed:
1000 of No. 1 capsules
Ethyl cellulose 9.0g
Stearic acid 15.0g
Triethyl citrate 4.5g
Pulvis Talci 30g
Dehydrated alcohol adds to 300ml
Medicine layer is formed: clothing film is formed:
Tartraric rosiglitazone 8g cellulose acetate 12g
PVPk30 8g Macrogol 4000 1.5g
Lactose 20g Diethyl phthalate 1.5ml
Pulvis Talci 6gAcetone/water (14/5/1) adds to 400ml
30% alcoholic solution adds to 200ml
Technology: with in No. 1 capsule shells, put into coating pan, the sheet bed tempertaure sprays into the waterproof coating solution (being made in dehydrated alcohol by stearic acid, ethyl cellulose, triethyl citrate, Pulvis Talci dissolution) for preparing for 45 ℃, after the coating weightening finish 15%, capsule is locked, the coating weightening finish is placed 12h down for 15%, 45 ℃ again, promptly gets and prevents water ballonet; With Tartraric rosiglitazone, lactose, Pulvis Talci dissolving is scattered in 2% PVPk30 30% alcoholic solution, be mixed with the medicine layer coating solution, the air bag for preparing is put into coating pan, adopt conventional film coating method at the outer packaging medicine layer of air bag, calculate the coating weightening finish with the rosiglitazone amount, every capsules contains rosiglitazone 8mg, adopt the identical operations method that the controlled release layer coating solution for preparing is wrapped on the pastille air bag, form clothing film, coating weightening finish 8～12%, place 24h under 45 ℃ of conditions, promptly get the floating controlled release preparation of Tartraric rosiglitazone air sac stomach.Measure according to the described method of embodiment 1 and to hold buoyancy, the result shows, the buoyancy of holding of the stomach floating preparation of present embodiment preparation does not reduce in 12 hours.Release test is measured according to 2005 editions one drug release determination first method of Chinese Pharmacopoeia (appendix C), is dissolution medium with the hydrochloric acid 900ml of 0.1mol/L, and temperature is (37 ± 0.5) ℃, rotating speed is under the 100r/min condition, operation in accordance with the law, timing when running begins certainly is respectively at 0.5,1,2,4,6, the 8h sampling and measuring, the cumulative release curve as shown in Figure 11.
Embodiment 8
Air bag is formed: medicine layer is formed:
1000 gentamycin sulfate 40g of No. 0 capsule
Ethyl cellulose 12.0g polyvidone k30 15g
Stearic acid 20.0g ethyl cellulose 30g
Triethyl citrate 6.0g Pulvis Talci 4g
Pulvis Talci 4.5gDehydrated alcohol adds to 500ml
80% alcoholic solution adds to 600ml
Clothing film is formed:
Ethyl cellulose 10g
Macrogol 4000 1.2g
HPMC 1.2g
80% alcoholic solution adds to 400ml
Technology: No. 0 capsule shells is put into coating pan, the sheet bed tempertaure sprays into the waterproof coating solution (being made in 80% alcoholic solution by stearic acid, ethyl cellulose, triethyl citrate, Pulvis Talci dissolution) for preparing for 45 ℃, after the coating weightening finish 15%, capsule is locked, the coating weightening finish 15% again, place 12h down, promptly get and prevent water ballonet for 45 ℃; With gentamycin sulfate, in the polyvidone k30 alcoholic solution that lactose is suspended in, be mixed with the medicine layer coating solution, the air bag for preparing is put into coating pan, adopt conventional film coating method at the outer packaging medicine layer of air bag, calculate the coating weightening finish with the gentamycin amount, every capsules contains gentamycin 40mg, adopt the identical operations method that the controlled release layer coating solution for preparing is wrapped on the pastille air bag, form clothing film, place 24h under 12%, 45 ℃ of condition of coating weightening finish, promptly get the floating controlled release preparation of bladder-type gentamycin sulfate stomach.Measure according to the described method of embodiment 1 and to hold buoyancy, the result shows, the buoyancy of holding of the stomach floating preparation of present embodiment preparation does not reduce in 12 hours.Degree of putting test is measured according to 2005 editions one drug release determination first method of Chinese Pharmacopoeia (appendix C), is dissolution medium with the hydrochloric acid 900ml of 0.1mol/L, and temperature is (37 ± 0.5) ℃, rotating speed is under the 100r/min condition, operation in accordance with the law, timing when running begins certainly is respectively at 0.5,1,2,4,6, the 8h sampling and measuring, the cumulative release curve as shown in Figure 12.
Embodiment 9
Air bag is formed:
No. 1 enteric coated capsule is every 1000 soon
Medicine layer is formed: clothing film:
Gentamycin sulfate 40g Eudragit RS100 2.5g
Eudragit RL100 45g base cellulose 2.0g
Ethyl cellulose 20g Polyethylene Glycol 0.8g
Polyethylene Glycol 10g Triethyl citrate 0.8g
90% alcoholic solution 1000ml, 90% ethanol 100ml
Technology: with gentamycin sulfate, Eudragit RL100, ethyl cellulose, Polyethylene Glycol is dissolved in 90% alcoholic solution, be mixed with the medicine layer coating solution, No. 1 enteric capsule shell is put into coating pan, adopt conventional film coating method at the outer packaging medicine layer of air bag, calculate the coating weightening finish with the gentamycin amount, every capsules contains gentamycin 40mg, adopt the identical operations method that the controlled release layer coating solution for preparing is wrapped on the pastille air bag, form clothing film, coating weightening finish 15%～18%, place 24h under 45 ℃ of conditions, promptly get the floating controlled release preparation of bladder-type gentamycin sulfate stomach.Measure according to the described method of embodiment 1 and to hold buoyancy, the result shows, the buoyancy of holding of the stomach floating preparation of present embodiment preparation does not reduce in 12 hours.The release test is measured according to 2005 editions one drug release determination first method of Chinese Pharmacopoeia (appendix C), hydrochloric acid 900ml with 0.1mol/L is a dissolution medium, and temperature is (37 ± 0.5) ℃, and rotating speed is under the 100r/min condition, operation in accordance with the law, timing when white running begins is respectively at 0.5,1,2,4, the 6h sampling and measuring, the cumulative release curve is as shown in Figure 13.
Embodiment 10
Air bag is formed:
1000 of No. 0 capsules
Citric acid 7.5g
Sodium bicarbonate 5g
Eudragit?RS 15g
Stearic acid 9.0g
Triethyl citrate 4.5g
Pulvis Talci 3.0g
Dehydrated alcohol adds to 400ml
Medicine layer is formed: the extended release coatings film is formed:
Gentamycin sulfate 40g Eudragit RS 10g
Polyvidone k30 40g Eudragit RL 3g
Lactose 30g Macrogol 4000 1.5g
Pulvis Talci 4g Diethyl phthalate 15ml
Dehydrated alcohol adds to 600ml 80% alcoholic solution and adds to 400ml
Technology: the sodium bicarbonate of recipe quantity and citric acid are packed in No. 0 capsule shells, put into coating pan with No. 0 capsule shells, put into coating pan, the sheet bed tempertaure sprays into the waterproof coating solution (being made in dehydrated alcohol by EudragitRS and triethyl citrate, stearic acid, Pulvis Talci dissolution) for preparing for 45 ℃, after the coating weightening finish 15%, capsule is locked, and the coating weightening finish 15% again, place 12h down, promptly get air bag for 45 ℃; With gentamycin sulfate, in the polyvidone k30 alcoholic solution that lactose is suspended in, be mixed with the medicine layer coating solution, adopt conventional film coating method, calculate the coating weightening finish with the gentamycin amount at the outer packaging medicine layer of air bag, every capsules contains gentamycin 40mg, adopt the identical operations method that the slow release layer coating solution for preparing is wrapped on the pastille air bag, form the extended release coatings film, coating weightening finish 15%, place 24h under 45 ℃ of conditions, promptly get the floating controlled release preparation of bladder-type gentamycin sulfate stomach.Measure according to the described method of embodiment 1 and to hold buoyancy, the result shows, the buoyancy of holding of the stomach floating preparation of present embodiment preparation does not reduce in 12 hours.The release test is measured according to 2005 editions one drug release determination first method of Chinese Pharmacopoeia (appendix C), hydrochloric acid 900ml with 0.1mol/L is a dissolution medium, temperature is (37 ± 0.5) ℃, rotating speed is under the 100r/min condition, operation in accordance with the law, from the timing of when beginning running, respectively at 0.5,1,2,4,6, the 8h sampling and measuring, the cumulative release curve as shown in Figure 14.
Embodiment 11
Air bag is formed:
1000 of No. 0 capsules
Ethyl cellulose 9.0g
Stearic acid 15.0g
Triethyl citrate 4.5g
Pulvis Talci 3.0g
80% alcoholic solution adds to 300ml
Medicine layer is formed: the extended release coatings film is formed:
Gentamycin sulfate 30g Eudragit RS 15g
PVPk30 40g Eudragit?RL 10g
Lactose 30g triethyl citrate 5ml
Pulvis Talci 8gPulvis Talci 5g
70% ethanol 500ml Macrogol 4000 10g
Dehydrated alcohol adds to 600ml
Technology: No. 0 capsule shells is put into coating pan, the sheet bed tempertaure sprays into the waterproof coating solution (being made in 80% alcoholic solution by stearic acid, ethyl cellulose, triethyl citrate, Pulvis Talci dissolution) for preparing for 45 ℃, after the coating weightening finish 15%, capsule is locked, the coating weightening finish 15% again, place 12h down, promptly get and prevent water ballonet for 45 ℃; With gentamycin sulfate, in the polyvidone k30 alcoholic solution that lactose, Pulvis Talci are suspended in, be mixed with the medicine layer coating solution, adopt conventional film coating method at the outer packaging medicine layer of air bag, calculate the coating weightening finish with the gentamycin amount, every capsules contains gentamycin 40mg.Adopt the identical operations method that the slow release layer coating solution for preparing is wrapped on the pastille air bag, form the extended release coatings film, place 24h under 45 ℃ of conditions, promptly.Measure according to the described method of embodiment 1 and to hold buoyancy, the result shows, the buoyancy of holding of the stomach floating preparation of present embodiment preparation does not reduce in 12 hours.The release test is measured according to 2005 editions one drug release determination first method of Chinese Pharmacopoeia (appendix C), hydrochloric acid 900ml with 0.1mol/L is a dissolution medium, and temperature is (37 ± 0.5) ℃, and rotating speed is under the 100r/min condition, operation in accordance with the law, timing when white running begins is respectively at 0.5,1,2,4, the 6h sampling and measuring, the cumulative release curve is as shown in Figure 15.
Embodiment 12
Air bag is formed: 1000 medicine layers of No. 0 capsule are formed:
Ethyl cellulose 18.0g gentamycin sulfate 30g
Stearic acid 12.0g PVPk30 30g
Triethyl citrate 7.5g lactose 30g
Pulvis Talci 5.0g Magnesium stearate 4g
80% ethanol adds to 500ml 70% alcoholic solution and adds to 500ml
The extended release coatings film is formed: the rapid release coatings:
Eudragit RS 18g gentamycin sulfate 10g
Eudragit?RL 10g PVPk30 6g
Triethyl citrate 5g Pulvis Talci 1g
Pulvis Talci 5g Titanium dioxide 1g
80% ethanol adds to 500ml 70% alcoholic solution and adds to 200ml
Technology: No. 0 capsule shells is put into coating pan, the sheet bed tempertaure sprays into the waterproof coating solution (being made in 80% alcoholic solution by stearic acid, ethyl cellulose, triethyl citrate, Pulvis Talci dissolution) for preparing for 45 ℃, after the coating weightening finish 15%, capsule is locked, the coating weightening finish 15% again, place 12h down, promptly get and prevent water ballonet for 45 ℃; With gentamycin sulfate, lactose, polyvidone k30 is dissolved in 70% alcoholic solution, be mixed with the medicine layer coating solution, the air bag for preparing is put into coating pan, adopt conventional film coating method at the outer packaging medicine layer of air bag, calculate the coating weightening finish with the gentamycin amount, every capsules contains gentamycin 40mg, adopt the identical operations method that the slow release layer coating solution for preparing is wrapped on the pastille air bag, form the extended release coatings film, after placing 24h under 45 ℃ of conditions, adopt the identical operations method that the rapid release coating solution for preparing is wrapped in extended release coatings film skin, promptly get floating pair of release formulation of bladder-type gentamycin sulfate stomach.Measure according to the described method of embodiment 1 and to hold buoyancy, the result shows, the buoyancy of holding of the stomach floating preparation of present embodiment preparation does not reduce in 12 hours.The release test is measured according to 2005 editions one drug release determination first method of Chinese Pharmacopoeia (appendix C), hydrochloric acid 900ml with 0.1mol/L is a dissolution medium, and temperature is (37 ± 0.5) ℃, and rotating speed is under the 100r/min condition, operation in accordance with the law, timing when the running beginning is respectively at 0.5,1,2,4, the 6h sampling and measuring, the cumulative release curve is as shown in Figure 16.
Embodiment 13
Air bag is formed: medicine layer is formed:
1000 gentamycin sulfate 30g of No. 0 capsule
Ethyl cellulose 9.0g Eudragit RL100 45g
Stearic acid 15.0g ethyl cellulose 20g
Triethyl citrate 4.5g Polyethylene Glycol 10g
Pulvis Talci 3.0g90% alcoholic solution 1000ml
80% alcoholic solution adds to 300ml
Clothing film: rapid release coatings:
Eudragit RS100 10g gentamycin sulfate 10g
Ethyl cellulose 10g PVPk30 6g
Polyethylene Glycol 1.0g Pulvis Talci 2g
Triethyl citrate 0.8g70% alcoholic solution adds to 200ml
90% ethanol 100ml
Technology: No. 0 capsule shells is put into coating pan, the sheet bed tempertaure sprays into the waterproof coating solution (being made in 80% alcoholic solution by stearic acid, ethyl cellulose, triethyl citrate, Pulvis Talci dissolution) for preparing for 45 ℃, after the coating weightening finish 15%, capsule is locked, the coating weightening finish 15% again, place 12h down, promptly get and prevent water ballonet for 45 ℃; Gentamycin sulfate, Eudragit RL100, ethyl cellulose, Polyethylene Glycol are dissolved in 90% alcoholic solution, be mixed with the medicine layer coating solution, the air bag for preparing is put into coating pan, adopt conventional film coating method at the outer packaging medicine layer of air bag, calculate the coating weightening finish with the gentamycin amount, every capsules contains gentamycin 40mg, adopts the identical operations method that the clothing film coating solution for preparing is wrapped on the pastille air bag, form clothing film, weightening finish 15～18%.After placing 24h under 45 ℃ of conditions, adopt the identical operations method that the rapid release coating solution for preparing is wrapped in the clothing film skin, promptly get floating pair of release formulation of bladder-type gentamycin sulfate stomach.Measure according to the described method of embodiment 1 and to hold buoyancy, the result shows, the buoyancy of holding of the stomach floating preparation of present embodiment preparation does not reduce in 12 hours.The release test is measured according to 2005 editions one drug release determination first method of Chinese Pharmacopoeia (appendix C), hydrochloric acid 900ml with 0.1mol/L is a dissolution medium, and temperature is (37 ± 0.5) ℃, and rotating speed is under the 100r/min condition, operation in accordance with the law, timing when the running beginning is respectively at 0.5,1,2,4, the 6h sampling and measuring, the cumulative release curve is as shown in Figure 17.
Embodiment 14
Air bag is formed: slow release layer is formed:
1000 Ondansetron Hydrochloride 8g of No. 1 capsule
Ethyl cellulose 9.0g stearic acid 15g
Stearic acid 15.0g ethyl cellulose 30g
Triethyl citrate 4.5g polyvidone k30 18g
Pulvis Talci 3.0gPolyethylene Glycol 15g
80% ethanol adds to 500ml Pulvis Talci 12g
80% ethanol adds to 500ml
Technology: with in No. 1 capsule shells, put into coating pan, the sheet bed tempertaure sprays into the waterproof coating solution (being made in 80% alcoholic solution by stearic acid, ethyl cellulose, triethyl citrate, Pulvis Talci dissolution) for preparing for 45 ℃, after the coating weightening finish 15%, capsule is locked, the coating weightening finish is placed 12h down for 15%, 45 ℃ again, promptly gets and prevents water ballonet; Ondansetron Hydrochloride, stearic acid, ethyl cellulose, polyvidone, Polyethylene Glycol, Pulvis Talci dissolving are scattered in 80% alcoholic solution, be mixed with the slow release layer coating solution, the air bag for preparing is put into coating pan, adopt conventional film coating method at the outer bundled slow-releasing layer of air bag, calculate the coating weightening finish with the ondansetron amount, every contains ondansetron 8mg, promptly gets Ondansetron Hydrochloride air sac stomach float slow release preparation.Measure according to the described method of embodiment 1 and to hold buoyancy, the result shows, the buoyancy of holding of the stomach floating preparation of present embodiment preparation does not reduce in 12 hours.Release test is measured according to 2005 editions one drug release determination first method of Chinese Pharmacopoeia (appendix C), is dissolution medium with the hydrochloric acid 900ml of 0.1mol/L, and temperature is (37 ± 0.5) ℃, rotating speed is under the 100r/min condition, operation in accordance with the law, timing when running begins certainly is respectively at 0.5,1,2,4,6, the 8h sampling and measuring, the cumulative release curve as shown in Figure 18.
Embodiment 15
Air bag is formed: medicine layer is formed:
1000 Ondansetron Hydrochloride 8g of No. 1 capsule
Ethyl cellulose 10.0g polyvidone k30 3g
Stearic acid 15.0g mannitol 20g
Triethyl citrate 5.0g Polyethylene Glycol 5g
Pulvis Talci 3.0g Pulvis Talci 3g
80% alcoholic solution adds to 300ml 30% alcoholic solution and adds to 200ml
Clothing film is formed:
Ethyl cellulose 12g
Macrogol 4000 2.5g
HPMC 1.5g
Diethyl phthalate 1.5ml
80% alcoholic solution adds to 300ml
Technology: with in No. 1 capsule shells, put into coating pan, the sheet bed tempertaure sprays into the waterproof coating solution (being made in 80% alcoholic solution by stearic acid, ethyl cellulose, triethyl citrate, Pulvis Talci dissolution) for preparing for 45 ℃, after the coating weightening finish 15%, capsule is locked, the coating weightening finish is placed 12h down for 15%, 45 ℃ again, promptly gets and prevents water ballonet; Ondansetron Hydrochloride, mannitol, Polyethylene Glycol, polyvidone k30 are dissolved in 30% alcoholic solution, be mixed with the medicine layer coating solution, the air bag for preparing is put into coating pan, adopt conventional film coating method at the outer packaging medicine layer of air bag, calculate the coating weightening finish with the ondansetron amount, every contains ondansetron 8mg, adopt the identical operations method that the controlled release layer coating solution for preparing is wrapped on the pastille air bag, form clothing film, coating weightening finish 10%, place 24h under 45 ℃ of conditions, promptly get the floating controlled release preparation of Ondansetron Hydrochloride air sac stomach.Measure according to the described method of embodiment 1 and to hold buoyancy, the result shows, the buoyancy of holding of the stomach floating preparation of present embodiment preparation does not reduce in 12 hours.Release test is measured according to 2005 editions one drug release determination first method of Chinese Pharmacopoeia (appendix C), is dissolution medium with the hydrochloric acid 900ml of 0.1mol/L, and temperature is (37 ± 0.5) ℃, rotating speed is under the 100r/min condition, operation in accordance with the law, timing when running begins certainly is respectively at 0.5,1,2,4,6, the 8h sampling and measuring, the cumulative release curve as shown in Figure 19.
Embodiment 16
Air bag is formed:
1000 of No. 1 capsules
Ethyl cellulose 9.0g
Stearic acid 15.0g
Triethyl citrate 4.5g
Pulvis Talci 30g
Medicine layer is formed:
Ondansetron Hydrochloride 8.0g clothing film is formed:
Polyvidone 30 4.0g cellulose acetate 12.0g
Lactose 20.0g Macrogol 4000 2.0g
Pulvis Talci 6.0g Diethyl phthalate 15ml
30% alcoholic solution adds to 200ml acetone/water (14/5/1) and adds to 400ml
Technology: with in No. 1 capsule shells, put into coating pan, the sheet bed tempertaure sprays into the waterproof coating solution (being made in 80% alcoholic solution by stearic acid, ethyl cellulose, triethyl citrate, Pulvis Talci dissolution) for preparing for 45 ℃, after the coating weightening finish 15%, capsule is locked, the coating weightening finish is placed 12h down for 15%, 45 ℃ again, promptly gets and prevents water ballonet; With Ondansetron Hydrochloride, lactose, polyvidone k30, Pulvis Talci dissolution in 30% alcoholic solution, be mixed with the medicine layer coating solution, the air bag for preparing is put into coating pan, adopt conventional film coating method at the outer packaging medicine layer of air bag, calculate the coating weightening finish with the ondansetron amount, every contains ondansetron 8mg, adopt the identical operations method that the controlled release layer coating solution for preparing is wrapped on the pastille air bag, form clothing film, coating weightening finish 6%, place 24h under 45 ℃ of conditions, promptly get the floating controlled release preparation of Ondansetron Hydrochloride air sac stomach.Measure according to the described method of embodiment 1 and to hold buoyancy, the result shows, the buoyancy of holding of the stomach floating preparation of present embodiment preparation does not reduce in 12 hours.Release test is measured according to 2005 editions one drug release determination first method of Chinese Pharmacopoeia (appendix C), is dissolution medium with the hydrochloric acid 900ml of 0.1mol/L, and temperature is (37 ± 0.5) ℃, rotating speed is under the 100r/min condition, operation in accordance with the law, timing when running begins certainly is respectively at 0.5,1,2,4,6, the 8h sampling and measuring, the cumulative release curve as shown in Figure 20.
Embodiment 17
Air bag is formed:
Watertight composition:
1000 of No. 1 capsules
Ethyl cellulose 9.0g
Stearic acid 15.0g
Triethyl citrate 4.5g
Pulvis Talci 3.0g
Dehydrated alcohol adds to 300ml
Sealing coat:
Lactose 30g
Polyvidone k30 3.0g
Dehydrated alcohol 200ml
Medicated layer is formed: clothing film:
Medicine layer: Eudragit RS100 2.5g
Ondansetron Hydrochloride 1.5g ethyl cellulose 2.0g
Eudragit RL100 5.0g Polyethylene Glycol 0.8g
Ethyl cellulose 2.0g Triethyl citrate 0.8g
Polyethylene Glycol 1.0g90% ethanol 100ml
90% alcoholic solution 100ml
Technology: No. 1 capsule shells is put into coating pan, the sheet bed tempertaure sprays into the waterproof coating solution (being made in dehydrated alcohol by stearic acid, ethyl cellulose, triethyl citrate, Pulvis Talci dissolution) for preparing for 45 ℃, after the coating weightening finish 15%, capsule is locked, the coating weightening finish 20% again, place 12h down, promptly get and prevent water ballonet for 45 ℃; Lactose is scattered in the ethanol solution of polyvidone k30 and makes sealing coat coating suspension, the air bag for preparing is put into coating pan, adopt conventional film coating method in the outer parcel of air bag sealing coat, coating weightening finish 25%; Ondansetron Hydrochloride, EudragitRL100, ethyl cellulose, Polyethylene Glycol are dissolved in 90% alcoholic solution, be mixed with the medicated layer coating solution, the air bag for preparing is put into coating pan, adopt conventional film coating method in the outer parcel of air bag medicated layer, calculate the coating weightening finish with the rosiglitazone amount, every capsules contains ondansetron 8mg; Eugragit RS100, ethyl cellulose, Polyethylene Glycol and triethyl citrate be dissolved in make the clothing film coating solution in 90% alcoholic solution, adopt conventional film coating method in the outer parcel of pastille air bag clothing film, coating weightening finish 15%～17%.Gastroretentive formulations is fixed on the spring top of holding the buoyancy analyzer shown in the accompanying drawing 4, puts into and measure cup, add 0.1N hydrochloric acid, the record preparation is suspended in the position of measuring cup, every 1 hour record once, and to 12 hours.The result shows, the buoyancy of holding of the floating shape preparation of stomach of present embodiment preparation does not reduce in 12 hours.The release test is measured according to 2005 editions one drug release determination first method of Chinese Pharmacopoeia (appendix C), hydrochloric acid 900ml with 0.1mol/L is a dissolution medium, temperature is (37 ± 0.5) ℃, and rotating speed is under the 100r/min condition, in accordance with the law operation, timing when the running beginning, respectively at 1,2,4, the 6h sampling and measuring, the cumulative release curve as shown in Figure 21.
Embodiment 18
Air bag is formed:
Watertight composition:
Ethyl cellulose 9.0g
Stearic acid 15.0g
Triethyl citrate 4.5g
Pulvis Talci 3.0g
Dehydrated alcohol adds to 300ml
Medicated layer is formed:
Medicine layer: clothing film:
Ondansetron Hydrochloride 1.5g Eudragit RS100 2.5g
Eudragit RL100 4.5g ethyl cellulose 2.0g
Ethyl cellulose 2.0g Polyethylene Glycol 1.0g
Polyethylene Glycol 1.0g Triethyl citrate 0.8g
90% alcoholic solution 100ml, 90% ethanol 100ml
Technology: No. 1 capsule shells is put into coating pan, the sheet bed tempertaure sprays into the waterproof coating solution (being made in dehydrated alcohol by stearic acid, ethyl cellulose, triethyl citrate, Pulvis Talci dissolution) for preparing for 45 ℃, after the coating weightening finish 15%, capsule is locked, the coating weightening finish 15% again, place 12h down, promptly get and prevent water ballonet for 45 ℃; Ondansetron Hydrochloride, EudragitRL100, ethyl cellulose, Polyethylene Glycol are dissolved in 90% alcoholic solution, be mixed with the medicated layer coating solution, the air bag for preparing is put into coating pan, adopt conventional film coating method in the outer parcel of air bag medicated layer, calculate the coating weightening finish with the rosiglitazone amount, every capsules contains ondansetron 8mg; Eugragit RS100, ethyl cellulose, Polyethylene Glycol and triethyl citrate be dissolved in make the clothing film coating solution in 90% alcoholic solution, adopt conventional film coating method in the outer parcel of pastille air bag clothing film, coating weightening finish 20%～22%.Gastroretentive formulations is fixed on the spring top of holding the buoyancy analyzer shown in the accompanying drawing 4, puts into and measure cup, add 0.1N hydrochloric acid, the record preparation is suspended in the position of measuring cup, every 1 hour record once, and to 12 hours.The result shows, the buoyancy of holding of the floating shape preparation of stomach of present embodiment preparation does not reduce in 12 hours.The release test is measured according to 2005 editions one drug release determination first method of Chinese Pharmacopoeia (appendix C), hydrochloric acid 900ml with 0.1mol/L is a dissolution medium, temperature is (37 ℃), and rotating speed is under the 100r/min condition, in accordance with the law operation, timing when white running begins, respectively at 1,2,4, the 6h sampling and measuring, the cumulative release curve as shown in Figure 22.
Embodiment 19
Air bag is formed: medicine layer is formed:
1000 ranitidine hydrochloride 50g of No. 0 capsule
Ethyl cellulose 12g polyvidone k30 40g
Stearic acid 20g lactose 30g
Triethyl citrate 6g Pulvis Talci 4g
Pulvis Talci 5g60% alcoholic solution adds to 1000ml
80% alcoholic solution adds to 400ml
Clothing film is formed: the immediate release drug layer
Ethyl cellulose 12g ranitidine hydrochloride 25g
Macrogol 4000 1.5g polyvidone k30 20g
HPMC 3.0g lactose 15g
Diethyl phthalate 3.0ml Pulvis Talci 8g
80% alcoholic solution adds to 400ml 30% alcoholic solution and adds to 300ml
Technology: No. 0 capsule shells is put into coating pan, the sheet bed tempertaure sprays into the waterproof coating solution (being made in 80% alcoholic solution by stearic acid, ethyl cellulose, triethyl citrate, Pulvis Talci dissolution) for preparing for 45 ℃, after the coating weightening finish 15%, capsule is locked, the coating weightening finish 15% again, place 12h down, promptly get and prevent water ballonet for 45 ℃; With ranitidine hydrochloride, lactose, Pulvis Talci, polyvidone k30 dissolution is in 30% alcoholic solution, be mixed with the medicine layer coating solution, the air bag for preparing is put into coating pan, adopt conventional film coating method at the outer packaging medicine layer of air bag, calculate the coating weightening finish with the ranitidine amount, every contains ranitidine 50mg, adopt the identical operations method that the controlled release layer coating solution for preparing is wrapped on the pastille air bag, form clothing film, coating weightening finish 12%, place 24h under 45 ℃ of conditions, parcel rapid release clothing layer calculates the coating weightening finish with the ranitidine amount, every release layer contains ranitidine 25mg, promptly gets the floating rapid release/controlled release preparation of bladder-type ranitidine hydrochloride stomach.Measure according to the described method of embodiment 1 and to hold buoyancy, the result shows, the buoyancy of holding of the stomach floating preparation of present embodiment preparation does not reduce in 12 hours.The release test is measured according to 2005 editions one drug release determination first method of Chinese Pharmacopoeia (appendix C), hydrochloric acid 900ml with 0.1mol/L is a dissolution medium, and temperature is (37 ± 0.5) ℃, and rotating speed is under the 100r/min condition, operation in accordance with the law, timing when the running beginning is respectively at 0.5,1,2,4, the 6h sampling and measuring, the cumulative release curve is as shown in Figure 23.
Embodiment 20
Air bag is formed:
1000 of No. 0 capsules
Citric acid 7.5g
Sodium bicarbonate 5g
Eudragit?RS 15g
Triethyl citrate 6g
Pulvis Talci 5g
Dehydrated alcohol adds to 400ml
Medicine layer is formed: the extended release coatings film is formed:
Ranitidine hydrochloride 75g Eudragit RS 14g
Polyvidone k30 50g Eudragit RL 6g
Magnesium stearate 10gMacrogol 4000 1.5g
30% alcoholic solution adds to 400ml Diethyl phthalate 6.0ml
80% alcoholic solution adds to 400ml
Technology: it is locked in No. 0 capsule shells that the sodium bicarbonate of recipe quantity and citric acid are packed into, put into coating pan, the sheet bed tempertaure sprays into the waterproof coating solution (being made in dehydrated alcohol by Eudragit RS, triethyl citrate, Pulvis Talci dissolution) for preparing for 45 ℃; The polyvidone k30 that ranitidine hydrochloride, magnesium stearate are suspended in is dissolved in the 30% alcoholic acid solution, be mixed with the medicine layer coating solution, adopt conventional film coating method at the outer packaging medicine layer of air bag, calculate the coating weightening finish with the ranitidine amount, every capsules contains ranitidine 75mg.Adopt the identical operations method that the sustained release coating liquid for preparing is wrapped on the pastille air bag, form the extended release coatings film, place 24h under 15%, 45 ℃ of condition of coating weightening finish, promptly get the floating controlled release preparation of bladder-type ranitidine hydrochloride stomach.Measure according to the described method of embodiment 1 and to hold buoyancy, the result shows, the buoyancy of holding of the stomach floating preparation of present embodiment preparation does not reduce in 12 hours.The release test is measured according to 2005 editions one drug release determination first method of Chinese Pharmacopoeia (appendix C), hydrochloric acid 900ml with 0.1mol/L is a dissolution medium, temperature is (37 ± 0.5) ℃, rotating speed is under the 100r/min condition, operation in accordance with the law, from the timing of when beginning running, respectively at 0.5,1,2,4,6, the 8h sampling and measuring, the cumulative release curve is as scheming shown in attached 24.Carry out the test of begle dog single-dose, result such as accompanying drawing 32 show that the blood drug level of stomach floating preparation of the present invention is compared more steady with ordinary preparation.
Embodiment 21
Air bag is formed: medicine layer is formed:
1000 ranitidine hydrochloride 75g of No. 0 capsule
Ethyl cellulose 9.0g polyvidone k30 40g
Stearic acid 15.0g lactose 30g
Triethyl citrate 4.5g Pulvis Talci 10g
Pulvis Talci 3.0g70% alcoholic solution adds to 1000ml
80% alcoholic solution adds to 400ml
Clothing film is formed:
Cellulose acetate 20g
Macrogol 4000 5g
Acetone/water (14:5:1) adds to 500ml
Technology: No. 0 capsule shells is put into coating pan, and the sheet bed tempertaure sprays into the waterproof coating solution (being made in 80% ethanol by ethyl cellulose, stearic acid, triethyl citrate, Pulvis Talci dissolution) for preparing for 45 ℃; With ranitidine hydrochloride, magnesium stearate, lactose, Pulvis Talci, polyvidone k30 dissolution in 70% alcoholic solution, be mixed with the medicine layer coating solution, adopt conventional film coating method at the outer packaging medicine layer of air bag, calculate the coating weightening finish with the ranitidine amount, every contains ranitidine 75mg.Adopt the identical operations method that the controlled release layer coating solution for preparing is wrapped on the pastille air bag, form clothing film, place 24h under 45 ℃ of conditions, promptly.Measure according to the described method of embodiment 1 and to hold buoyancy, the result shows, the buoyancy of holding of the stomach floating preparation of present embodiment preparation does not reduce in 12 hours.The release test is measured according to 2005 editions one drug release determination first method of Chinese Pharmacopoeia (appendix C), hydrochloric acid 900ml with 0.1mol/L is a dissolution medium, and temperature is (37 ± 0.5) ℃, and rotating speed is under the 100r/min condition, operation in accordance with the law, timing when the running beginning is respectively at 0.5,1,2,4, the 6h sampling and measuring, the cumulative release curve is as shown in Figure 25.
Embodiment 22
Air bag is formed:
1000 medicine layers of No. 0 capsule are formed:
Ethyl cellulose 15.0g ranitidine hydrochloride 50g
Stearic acid 10.0g PVPk30 30g
Triethyl citrate 4.5g lactose 30g
Pulvis Talci 3.0g Magnesium stearate 4g
80% alcoholic solution adds to 400ml 70% alcoholic solution and adds to 1000ml
The extended release coatings film is formed: the rapid release coatings:
Eudragit RS 8g ranitidine hydrochloride 25g
Eudragit?RL 8g PVPk30 6g
Triethyl citrate 5g Pulvis Talci 1g
Pulvis Talci 5g Titanium dioxide 1g
80% ethanol adds to 300ml 70% alcoholic solution and adds to 300ml
Technology: No. 0 capsule shells is put into coating pan, and the sheet bed tempertaure sprays into the waterproof coating solution (being made in 80% ethanol by ethyl cellulose, stearic acid, triethyl citrate, Pulvis Talci dissolution) for preparing for 45 ℃; With ranitidine hydrochloride, magnesium stearate, lactose, Pulvis Talci, polyvidone k30 dissolution is in 70% alcoholic solution, be mixed with the medicine layer coating solution, the air bag for preparing is put into coating pan, adopt conventional film coating method at the outer packaging medicine layer of air bag, calculate the coating weightening finish with the ranitidine amount, adopt the identical operations method that the slow release layer coating solution for preparing is wrapped on the pastille air bag, form the extended release coatings film, after placing 24h under 45 ℃ of conditions, adopt the identical operations method that the rapid release coating solution for preparing is wrapped in extended release coatings film skin, promptly get floating pair of release formulation of bladder-type ranitidine hydrochloride stomach.Measure according to the described method of embodiment 1 and to hold buoyancy, the result shows, the buoyancy of holding of the stomach floating preparation of present embodiment preparation does not reduce in 12 hours.The release test is measured according to 2005 editions one drug release determination first method of Chinese Pharmacopoeia (appendix C), hydrochloric acid 900ml with 0.1mol/L is a dissolution medium, and temperature is (37 ± 0.5) ℃, and rotating speed is under the 100r/min condition, operation in accordance with the law, timing when white running begins is respectively at 0.5,1,2,4, the 6h sampling and measuring, the cumulative release curve is as shown in Figure 26.
Embodiment 23
Air bag is formed: 90% alcoholic solution 1000ml
1000 clothing films of No. 0 enteric coated capsule:
Medicine layer is formed: Eudragit RS100 2.5g
Ranitidine hydrochloride 75g ethyl cellulose 2.0g
Eudragit RS100 25g Polyethylene Glycol 0.6g
Ethyl cellulose 15g Triethyl citrate 0.6g
Polyethylene Glycol 10g90% ethanol 100ml
Technology: with ranitidine hydrochloride, Eudragit RS100, ethyl cellulose, Polyethylene Glycol is dissolved in 90% alcoholic solution, be mixed with the medicine layer coating solution, No. 0 enteric capsule shell is put into coating pan, adopt conventional film coating method at the outer packaging medicine layer of air bag, calculate the coating weightening finish with the ranitidine amount, every capsules contains ranitidine 40mg, adopt the identical operations method that the controlled release layer coating solution for preparing is wrapped on the pastille air bag, form clothing film, coating weightening finish 15%～18%, place 24h under 45 ℃ of conditions, promptly get the floating controlled release preparation of bladder-type sulphuric acid ranitidine stomach.Measure according to the described method of embodiment 1 and to hold buoyancy, the result shows, the buoyancy of holding of the stomach floating preparation of present embodiment preparation does not reduce in 12 hours.The release test is measured according to 2005 editions one drug release determination first method of Chinese Pharmacopoeia (appendix C), hydrochloric acid 900ml with 0.1mol/L is a dissolution medium, temperature is (37 ± 0.5) ℃, and rotating speed is under the 100r/min condition, in accordance with the law operation, timing when the running beginning, respectively at 1,2,4, the 6h sampling and measuring, the cumulative release curve as shown in Figure 27.
Embodiment 24
Air bag is formed: clothing film:
1000 Eudragit RS100 of No. 0 capsule 10g
Ethyl cellulose 9.0g ethyl cellulose 10g
Stearic acid 15.0g Polyethylene Glycol 1.0g
Triethyl citrate 4.5g Triethyl citrate 0.8g
Pulvis Talci 3.0g90% ethanol 100ml
80% alcoholic solution adds to 300ml
Medicine layer is formed: the rapid release coatings:
Ranitidine hydrochloride 50g ranitidine hydrochloride 25g
Eudragit?RL100 45g HPMC 10g
Ethyl cellulose 20g Polyethylene Glycol 4g
Polyethylene Glycol 10g Pulvis Talci 2g
90% alcoholic solution 1000ml, 70% alcoholic solution adds to 200m
Technology: No. 0 capsule shells is put into coating pan, the sheet bed tempertaure sprays into the waterproof coating solution (being made in 80% alcoholic solution by stearic acid, ethyl cellulose, triethyl citrate, Pulvis Talci dissolution) for preparing for 45 ℃, after the coating weightening finish 15%, capsule is locked, the coating weightening finish 15% again, place 12h down, promptly get and prevent water ballonet for 45 ℃; Ranitidine hydrochloride, Eudragit RL100, ethyl cellulose, Polyethylene Glycol are dissolved in 90% alcoholic solution, be mixed with the medicine layer coating solution, the air bag for preparing is put into coating pan, adopt conventional film coating method at the outer packaging medicine layer of air bag, calculate the coating weightening finish with the ranitidine amount, every capsules contains ranitidine 50mg, adopts the identical operations method that the clothing film coating solution for preparing is wrapped on the pastille air bag, form clothing film, weightening finish 22～24%.After placing 24h under 45 ℃ of conditions, adopt the identical operations method that the rapid release coating solution for preparing is wrapped in the clothing film skin, promptly get floating pair of release formulation of bladder-type ranitidine hydrochloride stomach.Measure according to the described method of embodiment 1 and to hold buoyancy, the result shows, the buoyancy of holding of the stomach floating preparation of present embodiment preparation does not reduce in 12 hours.The release test is measured according to 2005 editions one drug release determination first method of Chinese Pharmacopoeia (appendix C), hydrochloric acid 900ml with 0.1mol/L is a dissolution medium, and temperature is (37 ± 0.5) ℃, and rotating speed is under the 100r/min condition, operation in accordance with the law, timing when white running begins is respectively at 0.5,1,2,4, the 6h sampling and measuring, the cumulative release curve is as shown in Figure 28.
Embodiment 25
Air bag is formed:
1000 of No. 6 capsules
Ethyl cellulose 6.0g
Stearic acid 10.0g
Triethyl citrate 3g
Pulvis Talci 2.0g
Dehydrated alcohol adds to 200ml
Medicine layer is formed: clothing film is formed:
Tartraric rosiglitazone 8g ethyl cellulose 12g
Polyvidone k30 3g Macrogol 4000 1.5g
Mannitol 8g HPMC 1.5g
Polyethylene Glycol 2g Diethyl phthalate 1.5ml
Pulvis Talci 1g80% alcoholic solution adds to 400ml
30% ethanol adds to 150ml
Technology: No. 6 capsule shells are put into coating pan, the sheet bed tempertaure sprays into the waterproof coating solution (being made in dehydrated alcohol by stearic acid, ethyl cellulose, triethyl citrate, Pulvis Talci dissolution) for preparing for 45 ℃, after the coating weightening finish 15%, capsule is locked, the coating weightening finish 15% again, place 12h down, promptly get and prevent water ballonet for 45 ℃; With Tartraric rosiglitazone, mannitol, Polyethylene Glycol, polyvidone k30 are dissolved in 30% alcoholic solution, be mixed with the medicine layer coating solution, the air bag for preparing is put into coating pan, adopt conventional film coating method at the outer packaging medicine layer of air bag, calculate the coating weightening finish with the rosiglitazone amount, every capsules contains rosiglitazone 8mg, adopt the identical operations method that the controlled release layer coating solution for preparing is wrapped on the pastille air bag, form clothing film, coating weightening finish 8%, place 24h under 45 ℃ of conditions, promptly get the floating controlled release preparation of Tartraric rosiglitazone air sac stomach.Measure according to the described method of embodiment 1 and to hold buoyancy, the result shows, the buoyancy of holding of the stomach floating preparation of present embodiment preparation does not reduce in 12 hours.Release test is measured according to 2005 editions one drug release determination first method of Chinese Pharmacopoeia (appendix C), is dissolution medium with the hydrochloric acid 900ml of 0.1mol/L, and temperature is (37 ± 0.5) ℃, rotating speed is under the 100r/min condition, operation in accordance with the law, timing when running begins certainly is respectively at 0.5,1,2,4,6, the 8h sampling and measuring, the cumulative release curve as shown in Figure 29.
Embodiment 26
Air bag is formed: medicine layer is formed:
1000 Ondansetron Hydrochloride 8g of No. 3 capsules
Ethyl cellulose 10.0g polyvidone k30 3g
Stearic acid 15.0g mannitol 12g
Triethyl citrate 5.0g Polyethylene Glycol 4g
Pulvis Talci 3.0g Pulvis Talci 2.5g
80% alcoholic solution adds to 300ml 30% alcoholic solution and adds to 200ml
Clothing film is formed:
Ethyl cellulose 12g
Macrogol 4000 2.5g
HPMC 1.5g
Diethyl phthalate 1.5ml
80% alcoholic solution adds to 300ml
Technology: with in No. 3 capsule shells, put into coating pan, the sheet bed tempertaure sprays into the waterproof coating solution (being made in 80% alcoholic solution by stearic acid, ethyl cellulose, triethyl citrate, Pulvis Talci dissolution) for preparing for 45 ℃, after the coating weightening finish 15%, capsule is locked, the coating weightening finish is placed 12h down for 15%, 45 ℃ again, promptly gets and prevents water ballonet; Ondansetron Hydrochloride, mannitol, Polyethylene Glycol, polyvidone k30 are dissolved in 30% alcoholic solution, be mixed with the medicine layer coating solution, the air bag for preparing is put into coating pan, adopt conventional film coating method at the outer packaging medicine layer of air bag, calculate the coating weightening finish with the ondansetron amount, every contains ondansetron 8mg, adopt the identical operations method that the controlled release layer coating solution for preparing is wrapped on the pastille air bag, form clothing film, coating weightening finish 10%, place 24h under 45 ℃ of conditions, promptly get the floating controlled release preparation of Ondansetron Hydrochloride air sac stomach.Measure according to the described method of embodiment 1 and to hold buoyancy, the result shows, the buoyancy of holding of the stomach floating preparation of present embodiment preparation does not reduce in 12 hours.Release test is measured according to 2005 editions one drug release determination first method of Chinese Pharmacopoeia (appendix C), is dissolution medium with the hydrochloric acid 900ml of 0.1mol/L, and temperature is (37 ± 0.5) ℃, rotating speed is under the 100r/min condition, operation in accordance with the law, timing when running begins certainly is respectively at 0.5,1,2,4,6, the 8h sampling and measuring, the cumulative release curve as shown in Figure 30.
The floating dynamic test of embodiment 27 stomaches
" test objective "
The kinetic property of research bladder-type stomach floating preparation
Air bag is formed: clothing film:
1000 Eudragit RS100 of No. 0 capsule 2.5g
2/capsule of barium bar ethyl cellulose 2.0g
Ethyl cellulose 9.0g Polyethylene Glycol 0.8g
Stearic acid 15.0g triethyl citrate 0.8g
Triethyl citrate 4.5g 90% ethanol 100ml
Pulvis Talci 30g
80% alcoholic solution adds to 300ml
Technology: with each No. 0 capsule two barium bars of packing into, capsule is not locked.No. 0 capsule shells is put into coating pan, the sheet bed tempertaure sprays into the waterproof coating solution (being made in 80% alcoholic solution by stearic acid, ethyl cellulose, triethyl citrate, Pulvis Talci dissolution) for preparing for 45 ℃, after the coating weightening finish 15%, capsule is locked, the coating weightening finish 15% again, place 12h down, promptly get and prevent water ballonet for 45 ℃; The air bag for preparing is put into coating pan, adopt conventional film coating method, form clothing film, weightening finish 22～24% at the outer parcel of air bag clothing film.After placing 24h under 45 ℃ of conditions.Measure according to the described method of embodiment 1 and to hold buoyancy, the result shows, the buoyancy of holding of the stomach floating preparation of present embodiment preparation does not reduce in 12 hours.Gastric floating capsule with this embodiment preparation is that model drug carries out the floating dynamic test of stomach.
" test method "
4 of experimenters, fasting 12 hours.
Take test meal before (8:00) takes medicine morning, after the dining, 2 gentamycin sulfate stomach floating preparations that the barium bar is housed swallowed, and can not chew; Noon, 12:00 took test meal once more.
In the test, the experimenter can freely drink water.
Accepting X line perspective behind swallowable capsule in 1,2,3,4,6,8 hour detects
" result of the test "
After 4 experimenters took the stomach floating preparation, the 8h capsule still swam in gastric (accompanying drawing 33).
Result of the test shows:
1, this stomach floating preparation is far longer than conventional tablet (30min～120min) in the gastric time of staying.
2, this stomach floating preparation in the gastric time of staying gastric emptying time (30min～120min), realize real Entogastric lingering much larger than bibliographical information.
3, this stomach floating preparation in the gastric time of staying much larger than the Entogastric lingering preparation of bibliographical information at time (3h～5h), realize real Entogastric lingering.
Embodiment 28
Air bag is formed: medicine layer is formed:
1000 gentamycin sulfate 40g of No. 0 capsule
Ethyl cellulose 12.0g polyoxyethylene 15g
Stearic acid 20.0g stearic acid 15g
Triethyl citrate 6.0g sodium bicarbonate 6g
Pulvis Talci 4.5g
80% alcoholic solution adds to 600ml
Technology: No. 0 capsule shells is put into coating pan, the sheet bed tempertaure sprays into the waterproof coating solution (being made in 80% alcoholic solution by stearic acid, ethyl cellulose, triethyl citrate, Pulvis Talci dissolution) for preparing for 45 ℃, after the coating weightening finish 15%, capsule is locked, the coating weightening finish 15% again, place 12h down, promptly get and prevent water ballonet for 45 ℃; With gentamycin sulfate, polyoxyethylene, stearic acid are crossed 100 mesh sieves, and mix homogeneously is made the dry-method coating powder; The air bag for preparing is put into coating pan, adopt centrifugal granulation at the outer packaging medicine layer of air bag, calculate the coating weightening finish with the gentamycin amount, every capsules contains gentamycin 40mg, adopt the identical operations method that the controlled release layer coating solution for preparing is wrapped on the pastille air bag, form clothing film, coating weightening finish 12%, place 24h under 45 ℃ of conditions, promptly get the floating controlled release preparation of bladder-type gentamycin sulfate stomach.Measure according to the described method of embodiment 1 and to hold buoyancy, the result shows, the buoyancy of holding of the stomach floating preparation of present embodiment preparation does not reduce in 12 hours.The release test is measured according to 2005 editions one drug release determination first method of Chinese Pharmacopoeia (appendix C), hydrochloric acid 900ml with 0.1mol/L is a dissolution medium, and temperature is (37 ± 0.5) ℃, and rotating speed is under the 100r/min condition, operation in accordance with the law, timing when white running begins is respectively at 0.5,1,2,4, the 6h sampling and measuring, the cumulative release curve is as shown in Figure 34.

Claims (16)

1. a stomach detention sustained and controlled release medicament releasing system is characterized in that comprising hollow capsule.
2. stomach detention sustained and controlled release medicament releasing system according to claim 1 is characterized in that comprising:
(1) the anti-water ballonet of forming by hollow capsule outer wrapping macromolecule filming material, hydrophobic material;
(2) medicated layer that constitutes by medicine and pharmaceutically acceptable excipient, medicated layer is wrapped in outside the air bag, and described medicated layer comprises medicine controlled releasing layer or slow release layer.
3. stomach detention sustained and controlled release medicament releasing system according to claim 2 is characterized in that also comprising release layer, is made up of medicine and excipient, is wrapped in outside slow release layer or the controlled release layer, makes two stomach detention sustained and controlled release medicament releasing systems of releasing.
4. according to claim 1,2 or 3 described stomach detention sustained and controlled release medicament releasing systems, it is characterized in that described hollow capsule is hard capsule and soft capsule.
5. stomach detention sustained and controlled release medicament releasing system according to claim 4 is characterized in that described hard capsule comprises common stomach dissolution type and enteric coated capsule, comprises the capsule of size capsule and special shape from No. 000 to No. 7.
6. stomach detention sustained and controlled release medicament releasing system according to claim 4 is characterized in that a certain amount of gas-forming agent also is housed in the capsule, comprises carbonate and pharmaceutically acceptable organic acid.
7. according to claim 2 or 3 described stomach detention sustained and controlled release medicament releasing systems, it is characterized in that medicated layer is a controlled release layer, constitute the gastric retention controlled release medicament releasing system, the employed excipient of controlled release layer comprises adhesive, lubricant, penetration enhancer, cosolvent and clothing film.
8. gastric retention controlled release medicament releasing system according to claim 7 is characterized in that described clothing film comprises macromolecular material, plasticizer, porogen etc., and the weightening finish of clothing film is 1%～40% of whole preparation.
9. according to claim 2 or 3 described stomach detention sustained and controlled release medicament releasing systems, it is characterized in that medicated layer is a slow release layer, constitute the stomach retention sustained-release drug release system, the excipient that slow release layer uses comprises slow-release material, adhesive, lubricant, penetration enhancer, cosolvent.
10. stomach retention sustained-release drug release system according to claim 9 is characterized in that also comprising gas-forming agent in the slow release layer that comprise sodium carbonate, sodium bicarbonate, magnesium carbonate, its consumption is 1%～20% of a slow release layer weight.
11. according to claim 1,2 or 3 described stomach detention sustained and controlled release medicament releasing systems is characterized in that described medicine comprises hangover medicine, treatment dementia medicine, anesthetics, acromegaly curative, analgesic, the treating asthma medicine, anticarcinogen, anticoagulant, antithrombotic, antiepileptic, medicine for treating diabetes, Bendectin, glaucoma treatment medicine, antihistaminic, anti-medicine, Parkinson's disease curative, the platelet curative of infecting, antirheumatic, spasmolytic and cholinergic drug, cough medicine, carbonic anhydrase inhibitors, the cardiovascular treatment medicine, cholinesterase inhibitor, nervus centralis disorder treatment medicine, central nervous excitation agent, contraceptive, the Cystic fibrosis curative, dopamine receptor gaonist, endometritis curative, the erection problem curative, the infertility treatment medicine, gastrointestinal drug, immunomodulator, immunosuppressant, the memory reinforcing medicine, migraine preparation, loosening all muscles medicine, the nucleoside analogues chemical compound, the osteoporosis therapy medicine is intended the parasympathetic nervous curative, prostaglandin, Psychotropic drug, calm, hypnosis and neuroleptic agent, treating skin disease medicine, steroid and hormone.
12. stomach detention sustained and controlled release medicament releasing system according to claim 11, it is characterized in that described medicine comprises rosiglitazone or its pharmaceutically acceptable salt, gentamycin or its pharmaceutically acceptable salt, ondansetron or its pharmaceutically acceptable salt, ranitidine or its pharmaceutically acceptable salt.
13. prepare the method for claim 1,2 or 3 described stomach detention sustained and controlled release medicament releasing systems, comprise the steps:
(1) air bag adopts two stage coatings in conjunction with heat-sealable technology, earlier the mixing coating solution with macromolecular material and hydrophobic material carries out coating to not locked capsule shells, stops coating when increasing weight 20～70% left and right sides to coating expectation total augment weight, after the intensive drying, with capsule locked after, remain 30～80% coating again, after coating is finished, placed 12～24 hours down for 45 ℃, after heat-sealable, make complete air bag, the watertight composition weightening finish is preferably 20%～60% for 10%～80% of capsules weight;
(2) use the ordinary coating technology to prepare medicated layer, to be medicine and excipient wrap up the outer wrapping slow-release material by coating with the air bag core again forms slow release layer or medicine is wrapped in air bag with the mixed with excipients that contains slow-release material and form slow release layer outward, makes the stomach retention sustained-release drug release system; Perhaps medicine and excipient are wrapped in air bag and wrap up one deck clothing film outward then and make controlled release layer, clothing film is made through film coating by pharmaceutically acceptable polymer, contain an amount of porogen in the film and meet water formation release micropore, the rate of release of control medicine, thus make the gastric retention controlled release medicament releasing system.
14. prepare the described two methods of releasing stomach detention sustained and controlled release medicament releasing system of claim 3, comprise the steps:
(1) air bag adopts two stage coatings in conjunction with heat-sealable technology, earlier the mixing coating solution with macromolecular material and hydrophobic material carries out coating to not locked capsule shells, stops coating when increasing weight 20～70% left and right sides to coating expectation total augment weight, after the intensive drying, with capsule locked after, remain 30～80% coating again, after coating is finished, placed 12～24 hours down for 45 ℃, after heat-sealable, make complete air bag, the watertight composition weightening finish is preferably 20%～60% for 10%～80% of capsules weight;
(2) use ordinary coating technology or centrifugal granulating technology to prepare medicated layer, to be medicine and excipient wrap up the outer wrapping slow-release material by coating with the air bag core again forms slow release layer or medicine is wrapped in air bag with the mixed with excipients that contains slow-release material and form slow release layer outward, makes the stomach retention sustained-release drug release system; Perhaps medicine and excipient are wrapped in air bag and wrap up one deck clothing film outward then and make controlled release layer, clothing film is made through film coating by pharmaceutically acceptable polymer, contain an amount of porogen in the film and meet water formation release micropore, the rate of release of control medicine, thus make the gastric retention controlled release medicament releasing system;
(3) use ordinary coating technology or centrifugal granulating technology to prepare release layer, medicine and excipient are wrapped in outside slow release or the controlled release layer, form the immediate release drug layer.
15. stomach detention sustained and controlled release medicament releasing system according to claim 2 is characterized in that also containing the contagion gown layer outside the watertight composition of described air bag, increasing weight is 10～40% of air bag.
16., it is characterized in that at described hollow capsule be the enteric coated capsule shell according to the described stomach detention sustained and controlled release medicament releasing system of claim 1.
CN 200810147445 2007-08-20 2008-08-18 Stomach detention sustained and controlled release medicament releasing system and preparation method Active CN101371822B (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CN 200810147445 CN101371822B (en) 2007-08-20 2008-08-18 Stomach detention sustained and controlled release medicament releasing system and preparation method
KR1020117006016A KR20110042366A (en) 2008-08-18 2008-11-04 Gastric retention drug delivery system, preparation method and use thereof
JP2011523290A JP2012500230A (en) 2008-08-18 2008-11-04 Gastric retention drug release system and method and use thereof
US13/059,553 US20110171275A1 (en) 2007-08-20 2008-11-04 Gastroretentive drug delivery system, preparation method and use thereof
PCT/CN2008/072917 WO2010020098A1 (en) 2008-08-18 2008-11-04 Gastric retention drug delivery system, preparation method and use thereof
EP08876775A EP2329810A4 (en) 2008-08-18 2008-11-04 Gastric retention drug delivery system, preparation method and use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200710143015 2007-08-20
CN200710143015.3 2007-08-20
CN 200810147445 CN101371822B (en) 2007-08-20 2008-08-18 Stomach detention sustained and controlled release medicament releasing system and preparation method

Publications (2)

Publication Number Publication Date
CN101371822A true CN101371822A (en) 2009-02-25
CN101371822B CN101371822B (en) 2013-06-26

Family

ID=45541132

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 200810147445 Active CN101371822B (en) 2007-08-20 2008-08-18 Stomach detention sustained and controlled release medicament releasing system and preparation method

Country Status (1)

Country Link
CN (1) CN101371822B (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102920682A (en) * 2011-08-11 2013-02-13 北京天衡药物研究院 Faropenem sodium gastric floating sustained-release preparation and its preparation method
CN104706613A (en) * 2015-03-20 2015-06-17 华侨大学 Preparation method of novel intra-gastric floating hollow sustained release tablet
CN108785245A (en) * 2018-07-13 2018-11-13 中国人民解放军军事科学院军事医学研究院 Stomach floating drug release combination unit
WO2018228441A1 (en) * 2017-06-14 2018-12-20 江苏恒瑞医药股份有限公司 Controlled release pharmaceutical composition and method for preparing same
CN109044981A (en) * 2018-08-07 2018-12-21 广州帝奇医药技术有限公司 A kind of Pregabalin intragastric floating slowly releasing piece and preparation method thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008122647A (en) 2006-11-13 2008-05-29 Sony Corp Display device, driving method of electro-optical element, and electronic equipment

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102920682A (en) * 2011-08-11 2013-02-13 北京天衡药物研究院 Faropenem sodium gastric floating sustained-release preparation and its preparation method
CN102920682B (en) * 2011-08-11 2017-11-24 北京天衡药物研究院有限公司 Faropenem sodium gastric floating slow-release preparation and preparation method
CN104706613A (en) * 2015-03-20 2015-06-17 华侨大学 Preparation method of novel intra-gastric floating hollow sustained release tablet
CN104706613B (en) * 2015-03-20 2018-01-16 华侨大学 A kind of stomach floats the preparation method of hollow sustained release tablets
WO2018228441A1 (en) * 2017-06-14 2018-12-20 江苏恒瑞医药股份有限公司 Controlled release pharmaceutical composition and method for preparing same
CN110214007A (en) * 2017-06-14 2019-09-06 江苏恒瑞医药股份有限公司 A kind of controlled release pharmaceutical compositions and preparation method thereof
TWI682789B (en) * 2017-06-14 2020-01-21 大陸商江蘇恒瑞醫藥股份有限公司 Controlled release pharmaceutical composition and preparation method thereof
CN108785245A (en) * 2018-07-13 2018-11-13 中国人民解放军军事科学院军事医学研究院 Stomach floating drug release combination unit
CN109044981A (en) * 2018-08-07 2018-12-21 广州帝奇医药技术有限公司 A kind of Pregabalin intragastric floating slowly releasing piece and preparation method thereof
CN109044981B (en) * 2018-08-07 2021-02-19 广州帝奇医药技术有限公司 Pregabalin gastric floating sustained release tablet and preparation method thereof

Also Published As

Publication number Publication date
CN101371822B (en) 2013-06-26

Similar Documents

Publication Publication Date Title
KR20110042366A (en) Gastric retention drug delivery system, preparation method and use thereof
Singh et al. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention
CN101636152B (en) Controlled-release preparation containing cilostazol and process for the preparation thereof
AU774957B2 (en) Hydrodynamically balancing oral drug delivery system
US20060099245A1 (en) Hydrodynamically balancing oral drug delivery system with biphasic release
CA2689049C (en) Gastroretentive system comprising an alginate body
US20100015224A1 (en) Programmable buoyant delivery technology
CN101371822B (en) Stomach detention sustained and controlled release medicament releasing system and preparation method
TW201127419A (en) Floating microgranules
US20110171275A1 (en) Gastroretentive drug delivery system, preparation method and use thereof
Gunda et al. Formulation development and evaluation of gastro retentive drug delivery systems-a review
KR20140131205A (en) Pharmaceutical composition containing highly water-soluble drug for sustained release
Rajak et al. Gastroretentive floating drug delivery system: an approach in gastroretentive drug delivery
Sanjay et al. Gastroretentive drug delivery system: Current approaches
RU2452472C2 (en) Delayed fixed-time pulsatile release dosage forms
Bhoyar et al. An overview of a gastro retentive floating drug delivery system
CN102764243A (en) Aspirin pulsed release pellets, its preparation and preparation method thereof
Tamizharasi et al. Floating Drug Delivery System.
CN101422453B (en) Verapamil hydrochloride delayed-release capsule and preparation method thereof
Choudhary et al. A Review: Gastro Retentive Drug Delivery System
WO2009007762A1 (en) Metronidazole containing extended release floating pharmaceutical composition
Kumar et al. A REVIEW ON GASTRO RETENTIVE FLOATING DRUG DELIVERY SYSTEM (GRDDS)
CN100391459C (en) Doxazosin mesilate slow releasing preparation
Kumar et al. AN UPDATE ON GASTRORETENTIVE FLOATING SYSTEMS
Ray et al. Floating Drug Delivry Systems: An Effort To Design.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: 100141 Beijing city Fengtai District Xiaotun Road No. 8 purple Park office block C C510

Patentee after: Beijing Tianheng Drug Research Institute

Address before: 100039 Beijing City, Fengtai District Jiang Jia Fen No. 329 Beijing Tianheng Pharmaceutical Institute

Patentee before: TEAM ACADEMY OF PHARMACEUTICAL SCIENCE

PE01 Entry into force of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Gastric retention drug delivery system and preparation method

Effective date of registration: 20210125

Granted publication date: 20130626

Pledgee: Beijing Zhongguancun bank Limited by Share Ltd.

Pledgor: Beijing Tianheng Drug Research Institute

Registration number: Y2021990000104

PC01 Cancellation of the registration of the contract for pledge of patent right
PC01 Cancellation of the registration of the contract for pledge of patent right

Date of cancellation: 20230217

Granted publication date: 20130626

Pledgee: Beijing Zhongguancun bank Limited by Share Ltd.

Pledgor: Beijing Tianheng Drug Research Institute

Registration number: Y2021990000104